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ABSTRACT 
 
High levels of the major angiogenic factor VEGF, have been reported in a 
number of cancer cell lines and in clinical specimens derived from breast. The 
forkhead transcription factors important for the regulation of many different 
physiological processes have been implicated in VEGF regulation in breast 
cancer. In this study, we have shown the interplay between FOXO3a and 
FOXM1 in breast cancer, with FOXO3a acting as a direct transcriptional 
repressor of VEGF. The mode of action of FOXO3a on the promoter of VEGF 
is dictated by events such as the competition with the VEGF transcriptional 
activator FOXM1, and the subsequent recruitment of a FOXO3a/HDAC2 
complex on the exact binding site. This action results in the repression of 
VEGF transcription and the decrease of VEGF expression and cell migration. 
Mutating the putative forkhead responsive element affects promoter activity, 
and silencing FOXO3a results in up-regulation of VEGF expression. Apart 
overexpression of FOXO3a also results in the repression of FOXM1 
expression, by its direct binding to the FOXM1 promoter. This event is also 
involved, indirectly, in the regulation of VEGF repression. Apart from FOXO3a 
and FOXM1, two other forkhead transcription factors that are implicated in 
breast cancer, FOXA1 and FOXC2, are also involved in the regulation of 
VEGF. FOXA1, a good prognosis factor in breast cancer, seems to inhibit the 
expression of FOXC2, a poor prognosis factor. FOXA1 is directly recruited on 
its binding site of the FOXC2 promoter, affecting its transcription and 
conferring a significantly low expression. Silencing FOXA1 results in high 
FOXC2 protein levels. The mode of action of these two factors between them 
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affects the expression of VEGF. These findings provide information on the 
cross-talk between different forkhead transcription factors and a crucial factor 
of tumour migration, invasion, angiogenesis and metastasis. 
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1. INTRODUCTION 
 
1.1 Cancer: An overview 
 
There are historical clues exhibiting that cancer has been affecting people 
since their existence on the planet. The oldest observations of the disease 
have been found in Egyptian ancient texts and mummies. Specifically, 
researchers had found osteosarcoma evidence in the fossilised bones of 
mummies. (www.lilly.gr) Interestingly, the first description of cancer was found 
in an Egyptian text circa 1600 BC, where eight cases of tumours were 
observed in the breast of women. The method of combating the disease was 
cauterisation with a special “fire” instrument. The disease, however, was 
described more analytically by the Greek “father of medicine” Hippocrates. 
Hippocrates stated in his texts, the existence of tumours which grow internally 
or externally on patients and resembled, due to the metastatic finger-like 
nature of cancer, the shape of a crab. 
 
Every year, around 3 million people are diagnosed with cancer in Europe and 
1.7 million deaths are associated to its diagnosis. The most common type of 
cancer, with an incidence of 13.2% of all cancers, is lung cancer followed by 
colorectal (13%) and breast (12.8%) cancer (Fig 1.1). These types of cancer 
are as well associated to a high incidence of mortality (Boyle* and J. Ferlay, 
2005). 
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Figure 1.1. Cancer incidence (2004) in Europe (both sexes) 
 
Every year more people are diagnosed with the disease within Europe. One 
major factor associated to the development of cancer is age and as 
westernised societies have an overgrowing ageing population, the increase of 
cancer patients is expected and inevitable. Most of the patients diagnosed 
with cancer are over 65 years old and only 1% of all cases occur in children. 
 
Cancer accounts as a genetic disease and until now it has not been clearly 
defined. However it can be accepted as a disease, which is characterised by 
the pathological expansion of a tissue resulting in uncontrollable spreading 
and subsequently, death. Ongoing research in the field of cancer has 
revealed part of the genetics behind the development of the disease. Physical 
changes such as mutations in gene categories such as tumour-suppressor, 
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oncogenes and stability genes are nowadays considered to be mostly 
responsible for tumourigenesis.  
 
Oncogenes are genes that when mutated or over-expressed contribute to 
converting a normal cell into a cancer cell. When mutated, these genes are 
constitutively active or active under conditions in which the wild-type gene is 
not. The activation of an oncogene can result from different reasons, varying 
from chromosomal translocations, gene amplifications and subtle intragenic 
mutations affecting crucial residues that regulate the activity of a gene product 
(Vogelstein and Kinzler, 2004). 
 
Tumour suppressor genes are genes whose protein products inhibit cell 
division and facilitate survival. Usually, mutations in these genes reduce the 
activity of the gene product and when mutated, they behave as recessive, 
which means that as long as the cell contains one wild type allele, tumour 
suppression continues. This type of genes seems to have a contrary function 
to oncogenes. 
 
The activation of oncogenes and the inactivation of tumour suppressor genes 
have similar physiological consequences: they drive the progression and 
increase in tumour cell numbers via the stimulation of cell proliferation, the 
inhibition of cell death and cell cycle arrest. This can be achieved through the 
activation of genes which drive the cell cycle, inhibition of the function of pro-
apoptotic genes or by facilitating the provision of nutrients through enhanced 
angiogenesis (Vogelstein and Kinzler, 2004). 
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Apart from the two classes of genes mentioned above, there is another class 
of genes that drive tumourigenesis in a different mode. These genes are 
called stability genes and are required for the repair of subtle mistakes made 
during DNA synthesis or those that are induced through the exposure to 
mutagens. These genes include mismatch repair (MMR), nucleotide - excision 
repair (NER) and base - excision repair (BER) genes (Charames and Bapat, 
2003: Slupphaug et al. 2003). Other stability genes control processes 
involving large proportions of chromosomes, such as those responsible for 
mitotic recombination and chromosomal segregation (e.g. BRCA1 and ATM). 
Stability genes minimise genetic changes and for this reason, this inactivation, 
leads to a higher rate of accumulation of mutations (Friedberg, 2003). 
Although the inactivation of the stability genes results in an increased 
vulnerability to genetic alterations in all genes, only mutations in oncogenes 
and tumour suppressor genes will confer a growth advantage to the cells. As 
with tumour suppressor genes, mutations in stability genes behave as 
recessive and both alleles need to be altered for the inactivation of a specific 
physiological effect (Vogelstein and Kinzler, 2004). 
 
Nowadays, a big variety of oncogenes, tumour suppressor and stability genes 
have been identified to contribute in carcinogenesis when mutated. Changes 
in the expression pattern of these genes leads to subsequent changes in 
signalling pathways which regulate cell proliferation and cell death. Such 
signalling pathways are comprised of a complex network of molecules 
including oncogenic proteins, tumour suppressors, sex hormone receptors, 
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growth factors and other transcription factors which interact with each other in 
one or multiple pathways which cross-talk between them. 
 
 
 
1.2 Breast Cancer 
 
As mentioned above, breast cancer is one of the most common types of 
cancer. Within the European Union, every 2.5 minutes a woman is diagnosed 
with breast cancer. Every 7.5 minutes a woman dies from the disease. Like all 
cancers, it happens due to a genetic “disregulation” of a cell. Although only 5-
10% of the patients developing breast cancer show a hereditary 
predisposition, the remaining patients develop the cancer due to a cell 
disregulation. 
 
The risk of a woman developing breast cancer, as with most types of cancer, 
is increasing with age. The risk of a woman developing breast cancer until the 
age of 39 is 0.5%, between the ages 40-59 years old is 4% and over 60 years 
old it is increasing to 7%. Different risk factors of breast cancer have been 
accounted. Apart from familial predisposition, women whose menstrual cycle 
started early or late, women who have a late menopause, women who receive 
estrogens at least 5 years post-menopausaly, women who never gave birth, 
and finally obese and women who are smoking.  
 
Men can also be affected by breast cancer, however the incidence is very low. 
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Figure 1.2 Estimated breast cancer incidence in Europe (2006) 
(European cancer observatory website) 
 
Although, the percentage of breast cancer patient mortality is still high, the 
fact of its decline is promising. 
 
The most important regulators of breast cancer growth are the estrogens, the 
most abundant of which is 17β estradiol. Oestrogens are steroid hormones 
synthesised mainly by the ovary and the placenta. They act through the 
nuclear estrogen receptors ERα and ERβ which control gene expression by 
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recruiting transcriptional co-factors (Paruthiyil et al., 2004; Sommer and 
Fuqua, 2001). Although these receptors are very similar, they exert different 
functions. ERα has a proliferative role and changes in its expression and 
activity can cause deregulation of various cellular processes, eventually 
leading to cancer (Sommer and Fuqua, 2001). In contrast to ERα, ERβ has 
anti-proliferative properties. Both receptors play distinct roles in breast 
development (Paruthiyil et al., 2004). ERα knockout mice have primitive 
mammary development (Couse and Korach, 1999), whereas ERβ knockout 
mice develop normal mammary glands (Krege et al., 1998). Therefore, only 
ERα is required for growth and differentiation of the mouse mammary gland. 
Studies indicate that ERβ may function as a tumour suppressor and its loss 
promotes breast carcinogenesis (Jarvinen et al., 2000; Roger et al., 2001; 
Skliris et al., 2001); however, the exact role of ERβ remains unknown. Other 
than ERα and ERβ, other regulators are involved as well in the growth of 
breast tumour cells. Several members of the epidermal growth factor (EGFR) 
family such as EGFR and HER2, have been shown to be over-expressed in 
breast carcinoma and are mediators of pathogenesis. Also, another growth 
factor that has been indicated to play a major role in breast cancer is the 
crucial regulator of physiological and pathological angiogenesis, VEGF-A. 
VEGF-A has been reported as a strong independent prognostic factor in both 
node-negative and node-positive breast carcinoma (Linderholm et al., 1998). 
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1.2.1 Breast Cancer treatment 
 
 
Systemic treatment for breast cancer can be given after (adjuvant) or before 
(neoadjuvant) locoregional treatment. Adjuvant therapy has been shown to 
improve survival and reduce the risk of recurrent breast cancer and is now the 
standard of care in the treatment of early stage breast cancer. With neo-
adjuvant therapy, about 50-70% of the patients will have enough tumour 
regression that mastectomy will be avoided. The choice of adjuvant treatment 
depends on the risk of relapse, estrogen receptor status, patient performance 
status and acceptability of treatment. The current treatment for breast cancer 
involves multimodality therapy including surgery, chemotherapy, radiotherapy, 
endocrine treatment and molecular therapy (Smith and Chua, 2006). 
 
In the last decades, the endocrine therapy most commonly used for the 
treatment of breast cancer is tamoxifen (Howell and Dowsett, 1997). 
Tamoxifen is a member of the selective estrogen receptor modulators 
(SERMs), which depending on the type of cancer, may act either as agonists 
or antagonists (Ali and Coombes, 2002). Tamoxifen is an anti-estrogen that 
blocks the binding of estrogen to its receptor. ERα is therefore a well-
established predictive marker of hormone sensitivity in breast cancer as only 
ERα-positive tumours can be treated with tamoxifen (Hayes, 2004). In 
contrast to normal breast cells, most breast cancer cells over-express ERα 
and are hormone-dependent and thus when oestrogen is removed, tumours 
shrink. Tamoxifen has antagonistic functions but also agonistic actions on the 
endometrium and bone. It also causes an increase risk of thromboembolism. 
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Another disadvantage of this treatment is that after a period of time, patients 
become resistant to tamoxifen. Tamoxifen is effective in both pre- and 
postmenopausal women in all age groups and has been shown to be more 
effective when given after chemotherapy rather than concurrently (Smith and 
Chua, 2006). Breast cancer patients who become resistant to tamoxifen are 
sometimes responsive to ICI182, 780 (faslodex), which is a pure anti-
oestrogen. In contrast to tamoxifen, it has no agonistic activities as it 
degrades the ER protein and can therefore target ER dependent tumours that 
are resistant to endocrine therapy (Horwitz and McGuire, 1980). Research is 
now focused in understanding the mechanisms that underlie endocrine 
resistance and the discovery of novel agents for the treatment of breast 
cancer.  
 
Various clinical trials have shown that aromatase inhibitors are also suitable 
for the treatment of breast cancer (Buzdar et al., 2007). These agents act by 
inhibiting oestrogen synthesis and include the non-steroidal anastrozole and 
letrozole and the steroidal compound exemestane. They are effective only in 
post-menopausal women and have been shown to improve disease free and 
metastatic free survival when compared to tamoxifen alone (ATAC trial) 
(Forbes et al., 2008). Nowadays, patients are switched to an aromatase 
inhibitor after two or three years of tamoxifen, as it has been shown that 
sequential treatment with tamoxifen followed by an aromatase inhibitor 
improves long term survival and reduces the risk of recurrent breast cancer 
(Dutta and Pant, 2007). 
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When chemotherapy is used as an adjuvant treatment, younger women tend 
to have the greatest benefit, particularly when they are lymph node positive 
and ER negative. The side effects usually include hair loss, fatigue, lethargy, 
oral mucositis, haematological toxicity and ovarian suppression with potential 
loss of fertility. The most common chemotherapeutic agents used currently 
are the anthracyclines doxorubicin and epirubicin. These drugs have been 
shown to be more effective than the traditionally used cyclophosphamide, 
methotrexate and fluorouracil (CMF) chemotherapy combination (Smith and 
Chua, 2006). Furthermore, evidence indicates that the addition of the newer 
class of chemotherapeutic agents, the taxanes, (paclitaxel and docetaxel) 
may improve survival in high-risk patients. Clinical trials are ongoing to 
establish the most effective chemotherapy combination for use in early stage 
breast cancer. Many of these drugs have already proven efficacy in women 
with metastatic breast cancer (Friedrichs et al., 2002). 
 
Presence of growth factor receptors has been correlated with poor disease-
free survival and resistance to endocrine therapy and chemotherapy and 
therefore inhibitors of growth factor activity have attracted increasing interest 
in the treatment of breast cancer (Spigel and Burstein, 2002). Anti-receptor 
antibodies and tyrosine kinase inhibitors are some of the strategies used to 
develop drugs to target the epidermal growth factor receptor (EGFR) and the 
related ErbB2/HER-2/neu. One of these inhibitors is the recently discovered 
Herceptin or trastuzumab (Slamon et al., 2001). Herceptin is a novel 
humanized monoclonal antibody that is directed against the external domain 
of the HER2 receptor. HER2 is over-expressed in 20% of breast cancers 
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(Stern, 2000). Results have shown that this inhibitor reduces the risk of 
recurrence by about 50% when given with or after chemotherapy for a year in 
women across all ages with early stage breast cancer (Engel and Kaklamani, 
2007). Clinical trials have also shown that herceptin improves survival when 
given in combination with paclitaxel or docetaxel in patients with metastatic 
disease (Azambuja et al., 2008). However, there is an increased risk of 
cardiotoxicity when given with the anthracyclines; hence Herceptin is given 
after chemotherapy and not concurrently (Sengupta et al., 2008). 
Furthermore, because Herceptin only targets one protein, it is limited in the 
range of patients it can reach.   
 
Recent studies reveal that the novel tyrosine kinase inhibitor Lapatinib ( Fig 
1.3) may also play a role in the treatment of breast cancer.  It targets both the 
epidermal growth factor receptor (EGFR) and HER2 receptor and has 
recently been approved by the US Food and Drug Administration (FDA) 
(Bilancia et al., 2007). Lapatinib (GW572016F) prevents tumour growth by 
inhibiting intracellular tyrosine kinase activity and in contrast to other EGFR 
tyrosine kinase inhibitors, such as Erlotinib and Gefitinib, it binds the inactive 
form of the receptor and therefore dissociates at a slower rate from the 
receptor resulting in a greater duration of effect on the target site (Wood et al., 
2004). 
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Figure 1.3. Molecular structure of Lapatinib (GW572016F) 
(www.lookchem.com) 
 
 
1.3 Tumour Angiogenesis and VEGF 
 
Angiogenesis is a physiological process involving the growth of new blood 
vessels from pre-existing ones. It is a normal process in growth and 
development, as well as in wound healing. However, this is also a 
fundamental step in the transition of tumours from a dormant state to a 
malignant state. Tumours induce blood vessel growth by secreting various 
growth factors allowing tumour expansion and subsequently the spread of 
tumour, or metastasis. 
 
Angiogenesis plays a central role in both local tumour growth and distant 
metastasis in various types of cancer, including breast cancer. Growth factors, 
such as VEGF, bFGF and PDGF can induce capillary growth into the tumour 
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allowing its progression. VEGF expression has been reported in a number of 
cancer cell lines and in several clinical specimens derived from breast. 
 
VEGF is a member of the platelet derived growth factor family of cystine-knot 
growth factors and its family in mammals consists of five glycoproteins 
referred to as VEGFA, VEGFB, VEGFC, VEGFD and placenta growth PGF 
(Ellis and Hicklin, 2008).  The most studied and important VEGF  variant is the 
8 exon-containing VEGFA. VEGFA is expressed in various forms due to 
alternative splicing (Fig 1.4). The mature products are 121-,165-, 183-,189- 
and 206-amino acid proteins with VEGFA165 being the one acting most 
strongly on endothelial cells and, together with VEGFA121, being 
overexpressed in solid tumours leading to the formation of new capillaries 
(Ellis and Hicklin, 2008; Price et al, 2001).  It is VEGFA, the one that is 
referred in most publications and in this thesis, commonly as VEGF. 
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Figure 1.4. Alternative splicing variants of VEGF (Hoeben et al. 2004)  
 
 
VEGF acts in a paracrine and an autocrine mode. When acting in a paracrine 
way, it is secreted by tumour cells exerting its effect in neighbouring or distant 
endothelial cells, whereas, when acting in an autocrine way, its action takes 
place in the cell which is expressed in (Lee et al, 2007). VEGF acts by binding 
in three different receptors, VEGFR1 (also named FLT1), VEGFR2 (also 
known as KDR1 or FLK1) and neuropilin 1 (NRP1) (Ferrara et al. 2003). From 
these receptors, VEGFR2 is the one that VEGF mediates initially and 
predominantly its effects in endothelial cells, since its kinase activity is 10-fold 
higher than VEGFR1. However, it has been reported that VEGFR1 sustains 
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angiogenesis and mediates the survival of endothelial cells via VEGF 
stimulation of the PI3K/Akt signalling pathway (Cai et al, 2003).  
 
 
Figure 1.5 VEGF family members are associated to different receptors 
dictating various cellular functions via downstream signalling cascades. 
 
Although it has been studied mainly in cells of the endothelium, VEGF affects 
many other cell types. Recently, it has been shown that is expressed in many 
cell types, including a variety of breast cancers (Schneider et al, 2005).  
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Overexpression of VEGF only, and not of the other known pro-angiogenic 
factors,  has been reported to be associated with poor prognosis and poor 
relapse-free survival in breast cancer. VEGF has also been shown to be 
present in breast tumours at levels that are, one average, 7-fold higher than in 
normal adjacent tissue (Yoshiji et al. 1996). Moreover, although the clinical 
significace of it has not been clearly elucidated, VEGF is the only pro-
angiogenic factor expressed throughout the breast tumour life cycle. In 
addition to the overexpression of VEGF in breast tumours with poor 
prognosis, VEGFR1 has been reported as a marker of aggressiveness in 
breast carcinoma, when acting in an autocrine manner (Lee et al, 2007). 
 
Recent research has correlated several breast cancer markers with VEGF 
expression. Tumour markers such as estrogen/estrogen receptor (ER), HER-
2 and BRCA-1 have been associated with VEGF expression in breast cancer. 
 
Estrogen modulates VEGF expression at the transcriptional level in breast 
cancer cells, suggesting a relationship between ER and VEGF. Estrogen-
dependent breast cancers show increased VEGF upon estrogen stimulation 
and furthermore VEGF levels have been associated with response to anti-
estrogen therapy in adjuvant treatment ( Buteau-Lozano et al., 2008; 
Linderholm et al,. 2000). However, additional studies also show that ER-
negative breast tumours have high VEGF expression and poor prognosis as 
well (Fuckar et al.,2006). Additionaly, another important breast cancer marker, 
HER-2, which is amplified in 20%-25% of breast cancers, has also been 
associated with VEGF upregulation. Patients presenting both HER-2 and 
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VEGF overexpression, have been reported to have the poorest outcome 
(Konecny et al., 2004). 
 
VEGF overexpression is an early step in breast cancer progression, and 
frequently occurs before tumour invasion, for example in ductal carcinomas in 
situ (Guidi et al., 1997). In this context, it is very interesting to note that the 
role of VEGF in breast cancer seems not to be limited to angiogenesis, as 
breast cancer cells express both VEGF and its receptors (VEGFR). Thus 
breast tumour cells may be able to promote their own growth and avoid 
apoptosis through VEGF. The above hypothesis, suggests an autocrine 
signalling loop of VEGF in breast cancer cells. Recently, it was proposed that 
in addition to antiapoptotic effects, autocrine VEGF signalling may contribute 
to cell migration and progression. An understanding of the VEGF-dependent 
signalling pathways in breast cancer is important for the complete knowledge 
and the subsequent development of treatment therapies of breast cancer. 
 
Antiangiogenic therapy is already being developed and explored with various 
clinical trials exibiting positive outcome in metastatic breast cancer.  The most 
mature, clinically, antiangiogenic agent is the recombinant, humanised 
monoclonal antibody against VEGF, named bevacizumab (GW786034B). 
Bevacizumab binds to all the isoforms of VEGFA and is normaly 
administrated in combination with other chemotherapy agents such as 
taxenes. Specifically the combination of bevacizumab with paclitaxel had 
given positive results in trials, as a first-line treatment for women with HER2-
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negative metastatic disease (Schneider BP and Sledge GW, 2007). Other 
combinational studies with bevacizumab in breast carcinoma are still ongoing.  
 
Other agents which inhibit VEGF, are studied as possible therapeutic agents 
of breast cancer. The most prominent are the small molecule receptor 
tyrosine kinase inhibitors (RTKIs) with specificity to VEGFRs. There are 
currrently many RTKIs being developed and several have already been tested 
with most studied, sunitinib (SU11248) and sorafenib (BAY43-9006). Phase II 
trials on previously treated breast cancer patients with either sunitinib or 
sorafenib, showed promising results in metastatic breast cancer, however 
single-activity has limited results (Miller KD et al., 2005;). The combination of 
sorafenib or sunitinib with bevacizumab is regarded to show more efficient 
results in the ongoing research of breast cancer therapy. 
 
A very intersesting approach of antiangiogenic therapy in breast cancer is the 
combination of VEGF-targeting agents with biological agents such as erbB-
targeting drugs. Both HER2 and EGFR appear to regulate VEGF. 
Specificaly,inhibiting HER2 or VEGF  results in decreased VEGF expression 
(Konecny GE et al., 2004). These observations led to the attempts of 
combinational trials blocking simultaneously the VEGF and erbB pathways. 
Positve results were obsereved in HER2-positive metastatic breast cancer 
patients who were administrated both bevacizumab and trastuzumab (Pegram 
MD et al., 2004). 
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Apart from bevacizumab in combination to trastuzumab, there have been 
studies with the sole use of tyrosine kinase inhibitors which inhibit the VEGF 
and ErbB pathways. These agents are pazopanib, that inhibits the VEGF 
tyrosine kinase receptors 1, 2 and 3 (VEGFR-1, -2, and -3), and lapatinib, that 
inhibits the HER1 and HER2 receptors, as mentioned earlier. Pazopanib and 
lapatinib, in combination, have shown efficacy in breast cancer patients and a 
hyperadditive proapoptotic effect in many differentcarcinoma cell lines, such 
as a non-small-cell lung carcinoma, a gastric cancer and a colon cancer cell 
line (Sloan and Scheinfeld, 2008).  The antiproliferative and proapoptotic 
synergisist effect of these two agents, was shown to be more potent than 
either of them alone. Pazopanib and lapatinib were shown to induce major 
changes in the transcriptome, specifically in proapoptotic mRNA species, and 
influence the activity of multiple kinases, apart from the ones which are 
already known to influence solely (Olaussen et all., 2009).  
 
Still, additional anti-VEGF combinational studies are needed and are being 
developed for metastatic breast cancer. For these studies and the future 
treatment of the disease, it would be very crucial to identify biomarkers which 
would guide antiangiogenic therapy in order to establish the optimum dose 
and to determine which patients might benefit most from a given drug. 
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1.4. The PI3-K signalling pathway in cancer 
 
The ERs and the phosphatidylinositol 3-kinase (PI3-K)/ protein kinase-B (PKB 
or Akt) signalling pathways are strongly implicated in the development of 
breast cancer. Deregulation of the PI3-K pathway has been demonstrated in 
many human breast cancers and has been linked to poor prognosis and 
endocrine therapy resistance. Recent evidence has shown that components 
of the PI3-K signalling cascade and ERα can be cross-regulated (Fry 2001).  
 
PI3-K was first identified as a lipid kinase activity associated with the products 
of viral oncogens and with activated protein-tyrosine kinases (Fry 1994) and 
was then implicated in several human cancers. Alterations in the PI3-K 
signalling cascades can lead to changes in a number of cell functions that 
contribute to the transformed phenotype, including cell growth and 
proliferation, differentiation, cell survival, adhesion and cell motility (Leevers 
et al. 1999). 
 
There are three classes of PI3-Ks, class I, II and III. Class I PI3-K’s are the 
most studied of them and have been implicated in tumourigenesis. PI3-K is a 
heterodimer kinase consisting of a p110 catalytic subunit and a p85 
regulatory subunit (Sun et al. 2001) which phosphorylates phosphatidyl-
inositols (PtdIns) on the 3’ hydroxyl group and converts PtdIns 4,5P2 to PtdIns 
3,4,5P3 (Leevers et al. 1999). PtdIns 3,4,5P3  binds to and activates the 
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Plecstrin Homology (PH) domain  of PDKs which in turn phosphorylates and 
activates the PH domain of the Protein Kinase B (PKB), also known as Akt, at 
the Thr-308 and Ser-473 with high affinity, stimulating PKB to protect cells 
from undergoing apoptosis (Fry 2001). 
 
The PKB (Akt) component of the PI3-K signalling pathway has been found to 
be a critical regulator of cell survival by phosphorylating a number of 
downstream proteins including the pro-apoptotic protein Bad, caspase-9 
which is also involved in apoptosis, the forkhead transcription factors (FKHR), 
Raf and p21-activated protein kinase (Sun et al. 2001). Additionally, it has 
been shown to increase the activity of telomerase, something that constitutes 
replication unlimited with its major subsequent results in cell biology. Another 
important effect of the activation of the PI3-K signalling is the regulation of 
angiogenesis via endothelial nitric-oxide synthase (eNOS) activation,  and its 
role in invasion and metastasis by the stimulation of matrix metalloproteinases 
(MMPs). 
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1.5 The Forkhead Transcription Factor family in cancer 
 
1.5.1. Forkhead transcription factors  
 
The Forkhead transcription factors are named after the first gene identified in 
Drosophila Melanogaster (Weigel et al., 1989) where the mutant embryo 
would show a two spiked-head structure instead of anterior and posterior gut. 
The 110-amino- acid DNA binding domain is highly conserved and over 100 
forkhead genes have been identified from yeast to human. At least 46 
members have been identified in the human forkhead box (FOX) gene super-
family (Katoh and Katoh, 2004). A unified nomenclature of the genes was 
revised in 2000 and 18 subfamilies (FOXA to FOXS) are grouped based on 
structural similarities and conservation levels in the forkhead DNA-binding 
domain (http://www.biology.pomona.edu/fox.html) (Kaestner et al., 2000). 
Three clusters of FOX genes are found on human chromosomes: FOXD2-
FOXE3 locus (1p33), FOXC1-FOXF2-FOXQ1 locus (6p25.3) and FOXC2-
FOXF1-FOXL1 locus (16q24.1) (Katoh and Katoh, 2004) 
 
The most conserved forkhead domain with nuclear localization signals (NLS) 
is also known as ‘winged helix’ domain because of the 3-D structure of two 
loops (wings) at the carboxy-terminus, 3 α-helices at the amino-terminus and 
3 β-sheets. The third α-helix, also referred to as the recognition helix, is the 
main DNA binding site, while the second wing influences binding stability and 
specificity (Wijchers et al., 2006). Therefore all forkhead transcription factors 
bind to DNA with the core consensus sequence RYMAAYA (R=A/G, Y=C/T, 
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M=A/C) (Carlsson and Mahlapuu, 2002; Overdier et al., 1994; Pierrou et al., 
1994) , or TRTTTAY (YRKTTRT) in reverse complement (Costa et al., 2001). 
Based on the presence or absence of a C-terminal basic region in the 
forkhead domain, the family is further grouped into two classes. While most of 
the FOX genes are in class 1 with a C-terminal basic region, FOXH, FOXM, 
FOXN, FOXO and FOXP are in class II (Katoh and Katoh, 2004).  
 
However, several other domains/ motifs have been identified in some 
subfamilies: transactivation domains, phosphorylation motifs, acetylation 
motifs, forkhead associated domain (FHA), nuclear receptor interaction motifs 
(Wijchers et al., 2006). For example, phosphorylation motifs have been shown 
to allow post-translational modification in FOXO and FOXA2 by Akt, IκKβ or 
JNK (c-jun N-terminal kinase), resulting in translocation or ubiquitination. 
Acetylation motifs in the FOXO forkhead domain allow acetylation of lysines 
by CBP/p300 to reduce transcriptional activity. Nuclear receptor interaction 
motifs LXXLL are located at the C-terminus of FOXO, FOXM1, FOXK1 and 
FOXP and mediate the interaction between forkhead transcription factors and 
nuclear receptors, including the androgen receptor, glucocorticoid receptor, 
and retinoic acid receptor (Van Der Heide et al., 2004). However, forkheads 
lacking this motif, such as FOXA and FOXH1, can interact with the androgen 
receptors too (Chen et al., 2005).   
 
 Functionally, forkhead proteins are involved in very diverse biological 
processes, including cell cycle regulation, survival, metabolism, 
immunoregulation and embryonic development. Therefore, deregulation of the 
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activity of various forkhead transcription factors can lead to congenital 
disorders or carcinogenesis (Lehmann et al., 2003; Wijchers et al., 2006). 
 
 
 1.5.2. FOXO transcription factors  
 
The human FOXO family consists of FOXO1 (FKHR), FOXO3a (FKHRL1), 
FOXO4 (AFX) and FOXO6, which are the mammalian homologues of daf-16 
in Caenorhabditis elegans.  
 
The mRNA of FOXO1, FOXO3a, and FOXO4 is ubiquitously expressed in all 
tissues but in different degrees (Greer and Brunet, 2005). Of the three, 
FOXO3a has the broadest expression pattern in embryo and adult tissues 
(Furuyama et al., 2000), and FOXO4 is more tissue specific (Biggs et al., 
2001).  
 
The physiological diverse functions of FOXO genes are best demonstrated in 
knock-out mice (Engstrom et al., 2003). Foxo1 null embryos die on embryonic 
day 10.5 because of defective angiogenesis (Furuyama et al., 2004). But 
Foxo3a and Foxo4 null mice are viable and grossly normal. Foxo3a -/- 
females are infertile because of premature ovarian failure (Hosaka et al., 
2004). In addition, they have defects in glucose uptake, over-proliferation of 
helper T–cells with multi-organ infiltrative lymphoproliferative disease (Lin et 
al., 2004), and increased apoptosis of neutrophils (Jonsson et al., 2005). 
These confirm the involvement of FOXO3a and FOXO4 genes in 
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development after organogenesis.  
 
FOXO transcription factors bind to a promoter with the consensus sequence 
(termed DBE for DNA binding element), TT(G/A)TTTAC (Furuyama et al., 
2000). An associated element, CTTATCA, is also identified in the promoter 
region of target genes, implying a presence of cooperation partner. A large 
number of gene promoters contain the DBE (Xuan and Zhang, 2005) which 
can explain its diversity in function. Once bound to the DNA, FOXO factors 
can act as transcriptional activators or repressors. FOXO transcription factors 
inhibit cell proliferation by regulating cell cycle or apoptosis.  
 
 
The ability of FOXO factors to induce cell cycle arrest, DNA repair and 
apoptosis makes them good tumour suppressor candidates. Theoretically, 
loss of FOXO function can lead to tumour development because of increased 
proliferation, decreased DNA repair and thus increased genomic instability. In 
addition, its interactions with both tumour suppressors and oncogenes 
increase its involvement in carcinogenesis.  
 
There have been observations that the presence of cytoplasmic FOXO3a in 
breast cancer correlates with poor survival (Hu et al., 2004). Furthermore, 
cytoplasmic FOXO3a also correlates well with the expression of p-Akt or IκKβ, 
which are correlated with tumour development and drug resistance. At the 
same time, over-expression of active FOXO factors reduces tumourigenicity 
with regards to tumour onset, size and progression in both nude mice 
transplanted with HER2 over-expressing cells (Yang et al., 2005) or deficient 
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for PTEN (Yang et al., 2005)). The FOXO-induced tumour suppression is 
obviously an attractive strategy to treat cancers with hyperactive PI3K/ Akt 
pathway.  
 
 The forkhead box (FOX) transcription factors are an extensive super family of 
transcription factors, consisting of more than 50 mammalian proteins that 
share homology in a 100 amino acid monomeric winged helix DNA binding 
domain (Kaestner et al. 2000). Recent work has identified as targets of PKB 
(also called Akt) the three members of the forkhead box, group O subfamily 
forkhead transcription factors FOXO1, FOXO3a and FOXO4. In the presence 
of growth factors, PI3-K phosphorylates PKB, which in turn phosphorylates 
and inactivates FOXO proteins. 
 
 
1.5.3. FOXM1 transcription factor  
 
FoxM1 (HFH-11B, Trident, Win or MPP2) is part of the mammalian Forkhead 
box transcription factor family is one of the most important  cell cycle 
regulators at both the G1/S and G2/M transitions. FOXM1 is localized mainly 
in the cytoplasm in late G1 to S phases and is translocated in the nucleus 
during the G2/M phase. At this stage, FOXM1 is phosphorylated by ERK1/2 
(Ma et al. 2005). 
 
The consensus binding site of FOXM1 is TAAACA, like a typical forkhead 
factor binding site on DNA. 
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In development FOXM1’ s disruption has been shown to result in postnatal 
death and histological analysis of the FOXM1 null embryos (day 10) reveal 
defects in the myocardium. More specifically, the orientation of the myocytes 
is irregular and their nuclei are polyploidy with a very high DNA content. This 
suggests that FOXM1 is required for normal DNA replication (S phase) and 
chromosomal segregation (M phase) within the cell cycle (Korver et al. 1998; 
Laoukili et al. 2005) 
 
Cell cycle is controlled by activation of several cyclin-dependent kinases 
(CDKs). CDKs are activated when their catalytic subunit is dephosphorylated 
by the Cdc25-A, -B and –C phosphatases. CDK activity is negatively 
regulated by CDK inhibitors p21Cip1, p27Kip1 and p16 INK4A. FOXM1 regulates 
the G1/S and G2/M transitions, mentioned above, by decreasing the nuclear 
levels of CDK inhibitors whilst activating Cdc25A and Cdc25B transcription 
(Wang et al. 2002). FOXM1, additionally, plays a role in mitosis and 
cytokinesis by transcriptionaly regulating cyclin B1, CENP-F, Aurora B and 
Polo-like kinase 1 (PLK1)  (Fig. 1.5) (Costa. 2005) 
 
In cancer, FOXM1 ‘s regulation of cell cycle progression suggests that in the 
absence of FOXM1 there is less likelihood of tumour cells to proliferate and 
generate large tumours. Moreover, FOXM1, has been shown to 
transcriptionaly regulate the expression of VEGF and promote growth and 
metastasis in glioma cells (Zhang et al. 2008) 
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Figure 1.6 FOXM1 activity requires CDKs, its components and 
downstream targets, for G1/S and G2/M transition. (adapted from Costa, 
2005) 
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1.5.4. FOXA1 transcription factor  
 
FOXA1 (Hepatocyte Nuclear Factor 3α) is a member of the forkhead 
transcription factors and plays a role in the differentiation and the 
development of liver, kidney, lung, prostate and breast (Friedman and 
Kaestner, 2006).  
 
FOXA1 is observed in breast tumours, being co-expressed with ERα in 
luminal breast tumours. FOXA1 acts as a good prognosis factor in breast 
cancer patients with ERα positive tumours as it is associated to sensitivity in 
endocrine therapy (Badve et al. 2007). FoxA1 has benn shown to assist the 
recruitment of ERα to several cis-regulatory elements in the genome followed 
by transcriptional activation in breast cancer cells (Carroll et al. 2005). FOXA1 
is associated to chromatin remodeling in breast cancer cells. The forkhead 
domain of FOXA1 resembles the globular domain of the linker histone H1 and 
as a result it replaces the linker histone to de-compact chromatin, in order to 
promote gene expression. FOXA1 helps the recruitment of ERα on a 
“loosened” chromatin environment and induces chromatin modifications in 
p27. Interestingly, it has been shown that FOXA1 is required for optimum 
expression of around 50% of ERα regulated genes and estrogen-induced 
proliferation (Thorat MA et al., 2008). Co-expression of GATA3, FOXA1 and 
ERα in breast cancer has been shown to dictate the phenotype of hormone-
dependent breast cancer. FOXA1 is over-expressed in ER-positive breast 
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cancer cell lines and has been reported as a good prognosis factor in breast 
cancer.   
 
 
1.5.5. FOXC transcription factors  
 
The FOXC members of the forkhead transcription factor family, are FOXC1 
(Mf1) and FOXC2 (Mfh1, FKHL14). These two forkhead transcription factors, 
which share the typical forkhead domain in their structure, have been found to 
play important roles in vascular endothelial and lymphatic development. 
FOXC1 and FOXC2 are expressed in the vasculature during development 
and their importance in development is depicted by the fact that 
FOXC1/FOXC2 null embryos die during embryonic development with defects 
in the vascular remodeling of primitive blood vessels and abnormal vascular 
connections between arteries and veins and arteriovenous malformations in 
general together with defects in the early sprouting and formation of lymphatic 
vessels (Kume, 2008; Hosaka et al., 2004; Seo et al., 2006).  
 
FOXC1 plays a role in normal ocular development with null mouse embryos 
displaying a phenotype of open eyelids, failure of anterior chamber formation, 
iris hypoplasia, attachment of the lens to the cornea, absense of the corneal 
endothelium and disorganised  corneal stroma. Apart from the ocular 
development, FOXC1 plays a role in the skeletal and cardiovascular 
development (Seo et al., 2006). 
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FOXC2 has been found to play a major role in arteriovenous development, as 
null mice show a widely defective morphology of blood vessels, FOXC2 as 
well is implicated in lymphatic development  as mice and humans 
heterozygous for FOXC2/Foxc2 have lymphedema (Fang et al. 2000).  
FOXC2 is an important regulator of the cardiovascular development as it has 
been observed that disruption of its expression in mice causes aortic arch 
patterning defects (Hayashi et al. 2008) Apart from development, FOXC2 has 
been shown to act as an activator of epithelial cell differentiation and 
metastasis in breast cancer (Mani et al. 2007) and as a regulator of 
angiogenesis via induction of integrin β3 (Itgb3)and the sunsequent Itgb3-
meidtaed endothelial cell adhesion and migration (Hayashi et al. 2008). 
Moreover, FOXC2 has been found to activate the epithelial to mesenchymal 
transition (EMT) of cells which is associated to metastasis of tumours (Hader 
et al. 2009) triggered by a number of factors, such as TGF-β1 and several 
EMT-inducing transcription factors, such as Snail, Twist, and Goosecoid. 
 
As mentioned above FOXC2 plays a role in metastasis in breast cancer. In 
this field of research it has been shown that FOXC2 is required for murine 
mammary cancer cells to metastasize to the lung. Additionaly, FOXC2 is 
correlated with the highly metastatic andaggressive basal-like human breast 
cancer type (Mani et al. 2007). Concluding, FOXC2 is taken as a marker of 
aggressiveness and metastasis in tumour development and is associated to 
poor clinical outcomes. 
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1.6 Implication of the Forkhead Transcription factors in angiogenesis 
 
Some FOXOs may potentially regulate angiogenesis in human tumours and 
have been implicated in the regulation of VEGF. VEGF has been shown to 
activate a number of signalling pathways such as PKC, MAPK/ERK and the 
PI3-K/Akt pathway. VEGF has been implicated in the regulation of 
transcription factors such as NF-κB, Egr-1, NFAT-1, Ets-1and Stat-3/5. More 
recently, it was reported that VEGF induces the phosphorylation and 
inactivation of the forkhead transcription factors via a PI3-K/PKB-dependent 
mechanism. 
 
Additionally in development, several members of the forkhead trasncription 
factor family take part in the genetic cascade that leads to endothelial 
differentiation. In the endothelium at least two subclasses of FOXs genes 
(FOXOs and FOXCs, as mentioned before) have been found to play a 
relevant role in vasculogenesis and angiogenesis (Dejana et al. 2007).  
 
Genetic inactivation of FOXO1 induces an embryonically lethal vascular 
phenotype with severe under-development of branchial arteries and dorsal 
aorta. It has been suggested that part of the vascular defects in the FOXO1 
null embryos may be due to a defective arterialisation response to VEGF. 
Furthermore, the triple conditional inactivation of FOXO1, FOXO3a and 
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FOXO4 in adult mice leads to large haemangiomata. In addition, FOXO3a 
null mice, which are viable, present significantly increased neovascularisation. 
Another significant observation, is that the Akt-1 (PKBα) knock-outs present 
strongly increased angiogenesis. Moreover, in vivo, FOXO3a deficiency 
upregulates the angiogenesis raleted gene eNOS which is essential for 
postnatal neovascularisation (Potente M et al. 2005). The above interesting 
observations, may suggest an endothelial cell tumour supressor role of the 
FOXO subclass of the forkhead transcription factors. 
 
As mentioned before, FOXM1, has also been implicated in angiogenesis. 
FOXM1 is an important cell cycle regulator and has been proposed to 
mediate cellular transformation into cancer cells. In regard to angiogenesis, it 
has been shown that the downregulation of FOXM1 leads to the inhibition of 
angiogenesis, migration and invasion in glioma cells (Wang et al. 2007). 
 
 
 
 
1.7 HDACs in breast cancer 
 
Genetic as well as epigenetic events play a key role in carcinogenesis and 
cancer progression. Epigenetic is a term used to describe changes in gene 
expression that are not due to changes in the DNA sequence and are 
inheritable from one generation to the next (Bird, 2002). Unlike genetic 
changes, epigenetic alterations are reversible. Some of the epigenetic events 
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include: acetylation, methylation, ubiquitination, phosphorylation, sumoylation 
and glycosylation. 
 
Acetylation is a chemical modification involving the transfer of an acetyl group 
from the acetyl co-enzyme to the ε-amino group of lysines in target proteins 
(Lin et al. 2006). Acetylation can occur in histones as well as other proteins 
and can have many effects. Histone acetylation affects histone structure by 
destabilizing nucleosomes leading to their dissociation or by inhibiting their 
stacking into the solenoid structure. Therefore acetylation leads to a less 
compact structure that allows access of transcription factors and other 
molecules such as RNA polymerase to the DNA and thus stimulate 
transcription of genes (Cress and Seto, 2000). Acetylation of a protein affects 
protein stability as acetylation and ubiquitination occur on lysine residues and 
so there are cross-talks between these two modifications (Caron et al., 2005). 
The stability of many known proteins, such as p53 and p73, has been shown 
to increase after lysine acetylation. The same lysines in these proteins are 
subject to ubiquitination and acetylation, therefore when acetylation occurs 
ubiquitination is prevented and stability of these proteins is increased (Caron 
et al., 2005) In other cases acetylation is needed to stimulate degradation, 
such as in the case of the Hypoxia-induced factor 1 (Hif-1), where its 
degradation occurs after binding to pVHL which then mediates its 
ubiquitination. Acetylation of one of the subunits of Hif-1, Hif-1a, enhances its 
binding to pVHL and therefore its degradation (Lee et al. 2004) More complex 
and indirect processes connecting ubiquitination and acetylation other than 
just through competition have also been reported (Caron et al., 2005). In 
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addition, acetylation plays a role in protein-protein interactions and 
localization. For example, acetylation of the transcription factor signal 
transducer and activator of transcription 3 (STAT3) induces its dimerization 
and translocation into the nucleus (Minucci and Pelicci, 2006). 
 
Genomic DNA is wrapped around 8 histones to form nucleosomes, which is 
the fundamental unit of chromatin.  Chromatin contains five types of histones: 
H1, H2A, H2B, H3, and H4. The nucleosome consists of an octamer of four 
core histones i.e. two H2A/H2B dimers and an H3/H4 tetramer, surrounded 
by 146bp of DNA (Yoo and Jones, 2006). H1 histone lies on the outer portion 
of the nucleosome and occurs in chromatin in about half the amount of the 
other types of histones. There is also the H5 histone that has similar functions 
to H1 (Marks et al., 2000). The amino-terminal and the carboxyl-terminal tails 
of histones protrude out of the nucleosomes and are subject to post-
translational modifications that regulate gene expression. Studies on the 
impact of these modifications in cellular processes are fast growing areas of 
research. Such a modification is the acetylation of histones by histone 
acetyltransferases (HATs) and deacetylation by histone deacetylases 
(HDACs).  Acetylation is correlated with an open chromatin structure, allowing 
transcription factors to access the promoters of target genes, therefore 
activating transcription (Nelson et al., 2007). Acetylation is involved in the 
regulation of DNA replication, repair and recombination (Masumoto et al., 
2005; Yang and Seto, 2007). Disordered HAT or HDAC activity has been 
linked to cancer. The fact that acetylation plays a very important role in the 
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regulation of gene expression has lead to the extensive study of HDACs in 
relation to cancer (Vigushin and Coombes, 2002).  
 
HATs acetylate histones leading to an open chromatin structure where 
transcription factors can easily reach the DNA and as a result transcriptional 
activity is induced. There are four families of HATs. The prototype family 
related to the yeast GCN5 includes human GCN5 and P/CAF (p300/CREB 
binding protein associating factor). The second family includes CREB binding 
protein (CBP) and p300 which mainly function as co-activators for many 
transcription factors. The third family includes the TAF250 protein which is 
part of the TFIID transcription factor complex that binds the TATA box and 
finally the fourth family, including SRC-1 and ACTR, function as co-activators 
for ligand-activated nuclear receptors. Other splice variants or related proteins 
exist that have HAT activity (Kouzarides, 1999). 
 
HDACs deacetylate histones leading to a very compact chromatin structure 
where transcription factors and other regulatory complexes cannot access the 
DNA, thereby gene transcription is repressed. HDACs usually interact as 
constituents of large protein complexes that downregulate genes through 
association with co-repressors (NcoR, SMRT), transcription factors (ER, p53, 
Mad/Max), cell cycle specific regulators (Rb, E2F), but they can also bind 
their target directly (Cress and Seto, 2000). For example, a decade ago the 
non-histone tumour suppressor p53 protein was shown to be acetylated by 
the recruitment of coactivators/HATs, a process very crucial for p53 function 
and activation of transcription of target genes ; Barlev et al., 2001). Another 
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example is the thyroid hormone receptor that activates transcription, upon 
binding of a ligand, by associating with the p300/PCAF histone 
acetyltransferases (Cress and Seto 2000). The proteins NCoR (Horlein et al., 
1995), SMRT (Chen and Evans, 1995), Sin3 and histone deacetylases 
(Alland et al., 1997) are part of this complex which is usually referred to as the 
Sin3 complex. Many proteins interact with HDACs directly or through other 
yet unidentified proteins (Brehm et al., 1998; Luo et al., 1998). 
 
 
 
 
Figure 1.7 HDAC action. Chromatin structure and remodeling by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). 
Acetylation of the N-terminal tails of histones leads to a loosening of the 
histone-DNA structure, allowing access of the transcriptional machinery 
(above) whereas deacetylation leads to tightening of the histone-DNA 
complex (below), repressing transcription. 
 
 
 
 
 
Dependent on sequence similarity and cofactor dependency, HDACs are 
grouped into two families: the classical HDAC family and the Sirtuin family of 
NAD+-dependent HDACs. Members of the classical HDAC family are divided 
in three classes. Class I HDACs include HDAC1, 2, 3, 8 and resemble the 
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RPD3 trascriptional regulator in yeast, class II include 4, 5, 6, 7, 9, 10 HDACS 
and resemble the yeast HDA1 deacetylase and class IV includes HDAC11. 
Classes I, II, IV have a similar sequence and are dependent on Zinc for their 
deacetylase activity. Class I is expressed in most cell types, while class II 
expression is more restricted. For this reason class II HDACS are thought to 
be involved in developmental processes and differentiation (de Ruijter et al., 
2003). The newly discovered HDAC 11 has conserved regions in the catalytic 
core region shared by both class I and II HDACs (Gao et al., 2002). Most 
HDACs contain a nuclear localisation signal (NLS) that targets them to the 
nucleus where most their substrates locate. Other HDACs can be cytosolic 
depending on other regulatory domains (de Ruijter et al., 2003). For example 
HDAC3 has both a NLS and a nuclear export signal (NES) suggesting that it 
can be also located in the cytoplasm (Yang et al., 2002). In most studies, 
HDAC3 is localized in the nucleus but this can be cell type specific. Class II 
HDACs shuttle between nucleus and cytoplasm depending on the signals 
they receive, while HDAC1 and HDAC2 are always in the nucleus as they 
lack a NES (Bertos et al., 2001).  
 
Functional HDACs are never found as single polypeptides but, with the 
exception of HDAC8, they form parts of multiprotein complexes along with 
other chromatin modifying enzymes or specific co-regulators. Both class I and 
class II HDACs play roles as transcriptional co-repressors by forming 
complexes with other DNA binding proteins and target the promoters of genes 
(Kumar et al., 2005). Although class I and II HDACs have a very similar 
catalytic site, they have differences in the entrance region of the active site 
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and the outer charge transfer relay system (Hildmann et al. 2006) Many class 
II HDACs are subject to posttranslational modifications such as sumoylation. 
HDAC 7 has been shown to act as a mitochondrial protein playing a role in 
apoptosis, as it translocates from the mitochondrial membrane to the 
cytoplasm in response to apoptotic signals(Bakin and Young. 2004). Class II 
HDACs are able to bind directly and inactivate some transcription factors 
leading to their transcriptional repression. 
 
The class III HDAC family called the sirtuin family includes seven members 
SIRT1-7. There are no sequence similarities amongst members and they 
require NAD+ as the cofactor important for their enzymatic activity (Nelson et 
al. 2007).  
 
It was recently shown that the mutational status of HDACs is very important in 
future pharmacogenetic treatment of cancer patients. Frameshift mutations in 
HDAC2 causing its loss of expression were seen in sporadic carcinomas with 
microsatellite instability and in cancer patients with hereditary non polyposis 
colorectal cancer syndrome. This loss of HDAC2 expression leads to tumours 
being less sensitive to the anti-cancer effects of HDAC inhibitors (Ropero et 
al., 2006). 
 
HDAC inhibitors (HDACi) have been proposed as new therapeutic agents in 
cancer, as they are important modulators of gene transcriptional activity. 
HDAC inhibitors have been shown to inhibit proliferation, cause cell cycle 
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arrest, promote differentiation, induce mitotic cell death, senescence and 
reactive oxygen species-induced cell death (Johnstone et al., 2002)  
 
HDACis are classified into four categories: hydroxamic acids, short-chain fatty 
acids, benzamide derivatives, and cyclic peptides. The very potent 
hydroxamic acids include compounds such as Trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA) and LAQ-824. They inhibit Class I 
and II HDACs (Lin et al., 2006). Crystallographic studies have shown that 
HDACs have a tubular catalytic site containing a zinc atom at its base and the 
hydroxamic moiety of these inhibitors bind this zinc and fit into this structure 
(Marks et al., 2000). Short-chain fatty acids are well tolerated by patients and 
clinical trials are carried out to evaluate them. Their disadvantage is that they 
have a short plasma half-life due to the rapid rate of metabolism and their 
non-specific mode of action, as well as the high doses needed for therapeutic 
effects. Agents like this are Valproate, Butyrate and Phenylbutyrate.. Finally, 
cyclic peptides, like depsipeptide and apicidin A, are the most structurally 
complex class of HDACis.  
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1.8 Objectives 
 
Angiogenesis, although a physiological process in human development, is 
associated to metastasis and tumour invasiveness in breast cancer. VEGF 
which is playing a fundamental role in angiogenesis, has been implicated and 
has been shown to be part of the signaling cascades dictating breast cancer. 
In these pathways, the family of the forkhead transcription factors are crucial 
and major players of the transcriptional regulation of several genes associated 
to breast cancer. The correlation of these factors in the subsequent 
transcriptional and translational regulation of VEGF could give an insight into 
the underlying mechanisms governing breast tumourigenesis and potentially 
help in the therapy of breast cancer. 
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2. MATERIALS AND METHODS 
 
 
2.1. Data bank analyses 
 
The NCBI, USCS and ensembl databases and blast software, were used for 
DNA and protein sequence analyses. 
 
2.2 Mammalian cell culture 
 
Cell Media 
 
The human breast cancer cell lines, MCF7, MDA-MB-231, SKBR3 and BT474 
were maintained in Dulbecco’s modified Eagle’s medium (Sigma) 
supplemented with 10% foetal calf serun (FCS) (Globepharm Ltd.), 2mM L-
glutamine and 100U/ml of penicillin/streptomycin (Sigma). The MDA-MB-
231FOXO3a(A3):ERa cells were maintained in DMEM without phenol red 
(GIBCO-BRL) supplemented with 10% Double Charcoal Stripped Foetal Calf 
Serum (DSS) (Globepharm Ltd.). The MCF7 FOXA1 cells were selected and 
maintained in the presence of Geneticin (Gibco) .  MCF7 FOXC2 cells were 
selected and maintained in the presence of 500 µg/ml Zeocyn (Invitrogen, 
UK).  
MDA-MB-FOXO3a:ERa  cells were cultured in DMEM without phenol red  
supplemented with 5% DSS prior to ELISA and  1% DSS prior to the wound 
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healing assay.  Cells treated with E2 (Sigma) were cultured in DMEM phenol 
red free whereas cells treated with 4-OHT (Sigma) and ICI (Sigma) were 
cultured in the DMEM with phenol red. 
 
 
2.3. Buffers for whole cell extracts from mammalian cell lines. 
 
HSB 400 mM KCl, 20 mM Tris. HCl pH 7.5, 
2 mM dithiothreitol (DTT), 1mM 
EDTA, 20% (v/v) glycerol, 1 tablet of 
protease inhibitor cocktail (Roche) 
PBS pH 7.5 138 mM NaCl, 20.4 mM Na2HPO4, 
2.7 mM KCl, 1.47 mM KH2PO4 
 
Table 2.1. Buffers used for  the whole cell extracts of mammalian cells. 
 
2.4. Protein concentration assay. 
 
The Bio-Rad DC protein assay was used to assay the protein concentrations 
of the samples. 20 µl of Reagent S were added to 1 ml of Reagent A to 
prepare the working reagent. 2 µl of the lysate were added to 100 µl of the 
above working reagent, in eppendorf tubes. Finally, 800 µl of Reagent B were 
added in the same tubes. The eppendorf content for each lysate, was added 
in disposable polystyrene cuvettes with 1 cm path length. The colour change 
was measured using a spectrophotometer at a wavelength of 750 nm (Lowry 
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method), the samples were zeroed against the sample with a control that did 
not contain any lysate. 
 
 
2.5 Sodium Dodecyl Sulphate- PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE). 
 
The protein gels were 7 % (w/v) acrylamide gels. First the running gel was 
poured to marked line (70%-80% the way up of the small glass plate) and 
2ml. of H2O (or Isopropanol) layered dropwise to give a levelled surface. The 
gel was left to polymerise for at least 30 minutes. Then, the water was 
removed, the stacking gel was poured and the combs were inserted. After 5 
minutes the gel was topped up. Before assembling the gel tank, the wells 
were washed using a syringe containing running buffer. 25 µg of protein 
samples plus an equal volume of 2X Laemmli; were loaded on the gel and 
were run for about one hour and a half at 100 Volts until the front of the 
loading buffer reached the end of the gel. In the first well of the gel, 2.5 µl of 
rainbow ladder (Amersham) were loaded, in order to be able to estimate the 
molecular weight of the bands. The electrophoresis was performed in 1X 
running buffer. 
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7 % Running gel 
ddH2O 3.7 ml 
Acrylamide 2.3 ml 
1 M. Tris HCl pH 8.8 3.7 ml 
10 % SDS 100 µl 
25 % Ammonium Persulphate (APS) 33 µl 
TEMED (Sigma) 13 µl 
 
 
5 % Stacking gel 
 
ddH2O 
 
3.5 ml 
Acrylamide 
 
825 µl 
1 M. Tris HCl pH 6.8 
 
625 µl 
10 % SDS 
 
50 µl 
25 % APS 
 
20 µl 
TEMED (Sigma) 
 
15 µl 
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Buffer Contents 
2X Laemmli buffer 50 mM Tris pH 6.8, 15 % glycerol, 2 
% SDS, 1mg/ml bromophenol blue 
dye, 1mM DTT 
Running buffer  25 mM Tris Base, 0.25 M glycine, 3.5 
mM SDS 
 
Table 2.2. Buffers used for SDS-PAGE.   
 
 
 
 
2.6. Western blotting. 
 
Transfer of the proteins. 
 
The proteins were then transferred on to PROTRAN nitrocellulose transfer 
membrane for western blotting (Schleicher & Schuell). The transfer took place 
in 1X transfer buffer for at least 2 hours at 0.6 A. 
 Then the transfer was checked for equal loading and transfer efficiency by 
Ponceau-S (Sigma) staining and washed with water and then with Tris 
Buffered Saline-Tween (TBS-T). The membranes were then blocked in 5 % 
(w/v) dry milk in TBS-T for about 30 minutes. 
 
 
69 
Buffer Contents 
1X Transfer buffer 24 mM Tris Base, 0.25 M NaCl 
TBS-T 20mM Tris, 150 mM NaCl, 1 % 
Tween (Sigma) 
 
Table 2.3. Recipe for the preparation of protein transfer buffers. 
 
 
 
Probing the membranes.   
 
All membranes were incubated with primary antibodies used at various 
dilutions in 5 % BSA plus 0.005 % NaAzide, overnight at 4o C. 
 
 
Primary Antibody Dilution Company 
FOXM1 (c-20) rabbit 
polyclonal IgG 
1:1000 Santa Cruz Biotechnology 
FOXO3a /FKHRL1 (H144) 
rabbit polyclonal IgG 
1:1000 Santa Cruz Biotechnology 
ERα (F-10) mouse monoclonal 
IgG 
1:1000 Santa Cruz Biotechnology 
FOXA1 (ab23738) rabbit 
polyclonal IgG 
1:1000 Abcam 
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FOXC1 (ab5079) goat 
polyclonal IgG 
1:1000 Abcam 
FOXC2  (F1054) rabbit 
polyclonal IgG 
1:1000 Sigma 
β-tubulin (H-235) rabbit 
polyclonal 
1:1000 Santa Cruz Biotechnology 
HDAC2 (2540) rabbit 
polyclonal 
1:1000 Cell Signalling 
VEGF (Ab46154) rabbit 
polyclonal 
1:1000 Abcam 
 
Table 2.4. List of primary antibodies used in western blotting. 
 
The membranes were then washed with TBS-T for about 60 minutes with 
changes every 10 minutes. Afterwards, the appropriate secondary antibodies 
(anti-mouse, anti-rabbit and anti-goat) were added on the membranes at 
1:1000 dilution in 5 % (w/v) milk in TBS-T for about 30 minutes. The 
membranes were washed again with TBS-T for about 60 minutes with 
changes every 10 minutes. 
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Developing the membranes. 
 
As soon as the membranes were washed, they were placed onto cling film. 
Then 2 ml of Enhanced Chemi-luminescence reagent (ECL) (Amersham) 
were poured over each membrane and left for 1 minute. The ECL reagent 
was removed and the membranes covered with cling film to avoid the 
membrane drying out. Finally, the membranes were exposed to ECL hyperfilm 
(Amersham) to visualise the proteins. 
 
 
2.7 Tissue culture: 
 
Maintenance of mammalian cell lines for the production of cell extracts 
for Real Time Quantitative Polymerase Chain Reaction (RTQ-PCR). 
    
The cells were maintained and treated with 4-OHT in the same way stated 
above and were trypsinised with 1 X trypsin in EDTA (Sigma) and centrifuged 
at 1200rpm for 5 minutes. The pellet formed was resuspended in 1 ml PBS. 
The lysate was added in eppendorf tubes and was centrifuged at 5000 rpm for 
5 minutes at 4 C. The pellet formed in the tubes was frozen at -80o C. 
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2.8 RNA extraction and determination. 
    
Total RNA was prepared by harvesting cells and extracted by guanidine 
isothiocyanate lysis followed by silica gel membrane purification (RNeasy kit, 
Qiagen Ltd., West Sussex, U.K.). Cells were disrupted by adding buffer RLT 
(Qiagen) containing 10% β-mercaptoethanol. Samples were homogenized, 
and 1 volume 70% ethanol was added. 700µl of the sample was added to an 
RNeasy mini column placed in a 2ml collection tube and centrifuged at 
10,000rpm for 15s in a microcentrifuge. Flow-through was discarded and 
700µl of buffer RW1 (Qiagen) was added followed by centrifugation for 15sec 
at 10,000rpm. Flow-through was again discarded. RNeasy column was 
transferred to a new collection tube and 500µl RPE (Qiagen) buffer added. 
Centrifugation step was repeated again. Another 500µl RPE was added 
followed by centrifugation at 10,000rpm for 2min. To elute, the RNeasy 
column was transferred to a new collection tube, 50µl RNase free water was 
added and centrifuged at 10,000rpm for 1 min. The concentration and purity 
of RNA were determined by measuring the spectrophotometric absorption at 
260 nm to 280 nm. 
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2.9 cDNA synthesis and Real-time Quantitative PCR (RTqPCR) 
 
Total RNA from samples was extracted using the RNeasy kit as explained 
above. RNA was then converted to cDNA using the Superscript III First-strand 
synthesis system for RT-PCR (Invitrogen LT). Real time PCR was performed 
with ABI PRISM 7700 Sequence Detection System using 2x SYBR Green 
Mastermix (Applied Biosystems) according to manufacturer’s instructions. 
One minute annealing at 60oC was used for 40 cycles. Gene-specific primer 
pairs were designed using the ABI Primer Express software. Primers were 
designed so that they produce a fragment of 50-150bp.  
 
Analysis was performed using the relative standard curve method. For the 
standard curve 1-2µg cDNA from each sample was mixed and diluted 1:2 and 
then 1:4 for four serial dilutions. As a control, primers for the L19 ribosomal 
housekeeping protein were used to normalize input RNA. The samples were 
diluted 1 in 4 and 2µl from each was used per reaction. Reaction mix also 
contained 22µl of SYBR Master Mix and the appropriate amount of primers 
which have been previously optimized, to a final volume of 25 µl. Efficiency of 
PCR was obtained from slope of standard curve (Eff = 10(-1/slope) -1). 90-
110% was expected with optimal primers with slope between -3.1 and -3.6. 
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Primer optimization 
 
Each primer set was optimized with 10ng cDNA standard to determine the 
minimum concentration required for maximum yield and minimum non-specific 
amplification. Dilutions of 50-900nM forward and reverse primers were tested 
with different combination (Table 2.5). The concentration that gave the lowest 
Ct value with standard DNA and highest with water was used in further 
experiments.  
 
 
 
 
 
 Forward Primer   
Reverse primer         50nM 300nM 900nM 
        50nM       50/50  300/50 900/50 
      300nM      50/300 300/300 900/300 
      900nM      50/900 300/900 900/900 
 
Table 2.5. Different dilutions of primers used in the primer optimisation 
prior to RTqPCR.    
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Primer Sequence 
VEGF (Operon) Forward 5'- GAAGTGGTGAAG TTCATGGATGTC -
3' 
Reverse  5'- CGATCG TTCTGTATCAGTCTTTCC -
3' 
L19 (Invitrogen) Forward 5'- GCGGAAGGGTACAGCCAAT -3' 
Reverse  5'- GCAGCCGGCGCAAA -3' 
FOXO3a (Invitrogen) Forward 5’ TCTACCAGTGGATGGATGGTGCGTT 
Reverse 5’ CGACTATGCCAGTGACAGGTTGTG 
FOXM1 (Invitrogen) Forward 5’TGCAGCTAGGGATGTGAATCTTC 3’ 
Reverse 5’ GGAGCCCAGTCCATCAGAACT 3’ 
FOXA1 (Operon) Forward 5’ TCTCTTGCTACCAGCATGGCT 3’ 
Reverse 5’ CCCGTCCTAAACACTTCCTAGCT 3’ 
HDAC2 (Invitrogen) Forward 5’ TTGGAGGAGGTGGCTACACAA 3’ 
Reverse 5’ ACAATCAAGGGCAACTGCAGT 3’ 
  
Table 2.6. List of primers used in RTqPCR 
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2.10 Transformation of bacteria. 
 
500 ml of LB agar were prepared and autoclaved. When the medium was 
cooled to 50 o C, 100 µg/ml of ampicillin antibiotic were added. In sterile 
conditions maintained by a flame, about 20 ml of the medium were poured 
into 90 mm plates. The plates were stored at 4 o C. 
  
1 µl of plasmid construct DNA was added to 50 µl of bacteria in one 
eppendorf tube. After incubating the tube in ice for 30 minutes, the bacteria 
were heat shocked in 42o C for 1 minute and then transferred in ice. The 
samples were then stored for 60 minutes at 37o C. The content of the tubes 
was spread on the agar plates which were stored overnight at 37o C. 
 
 
                                           
 2.11 Plasmid Maxipreparation. 
 
For the plasmid maxiprep, the HiSpeed Plasmid Maxi Kit (QIAGEN) was 
used. 250ml of LB containing 100µg/ml ampicillin or kanamycin was 
inoculated with 1 ml of an 8 hour culture of bacteria. Cultures were incubated 
at 37ºC overnight with vigorous shaking. 
The bacterial cells were then harvested by centrifugation at 6000x g for 15min 
at 4oC. Pellet was resuspended in 10ml Buffer P1(50mM Tris-HCl pH 8.0, 
10mM EDTA, 100µg/ml RNAse A) followed by addition of 10ml of Buffer P2 
(200mM NaOH, 1% SDS) and 10ml of Buffer P3 (3mM potassium acetate pH 
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5.5). The solution was mixed and lysates were poured into the barrel of the 
QIAfilter cartridge. Incubation at room temperature for 10min was followed. 
Solution was added to a previously equilibrated HiSpeed Maxi Tip (by addition 
of 10ml Buffer QBT), washed with 60ml Buffer QC (1M NaCl, 50mM MOPS 
pH 7.0, 15% ethanol) and DNA was eluted with 15ml Buffer QF (1.25M NaCl, 
50mM Tris-HCl pH 8.5, 15% Ethanol). DNA was precipitated by adding 10.5ml 
isopropanol and incubated at room temperature for 5min. The 
eluate/isopropanol was filtered through a syringe that is attached to a 
QIAprecipitator Maxi Module. After 70% ethanol was added, the 
QIAprecipitator was removed from the syringe as well as the plunger. The 
qiaprecipitator was then attached again and the plunger was inserted and by 
pressing air through the QIAprecipitator, the membrane was dried. The 
QIAprecipitator was then attached to a 5ml syringe and 1ml of buffer TE 
(10mM Tris-HCl, 1mM EDTA, pH 8) was used to elute DNA into a collection 
tube.  
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2.12 DNA quantification  
 
The concentration of DNA was measured by two different methods.  
The first was by using a BioRad spectrophotometer (Bio-rad Smart 
SpecTM3000 Spectrophotometer) which measures the optical density (OD) of 
the samples at 260nm. The formula used to calculate DNA concentration was: 
1 OD unit at 260nm = 50µg/ml DNA. 
 
The second method to quantify DNA samples was using a ND-1000 
spectrophotometer (NanoDrop Technologies) which measures instantly the 
DNA concentration upon the addition of 1 µl of sample without the use of 
cuvettes. 
 
 
2.13. Luciferase assay 
 
Cells were plated out in 96-well plates and transfected after 24 hours with 
20ng of the different luciferase reporter recombinant vectors and 5ng of renilla 
control constructs per well, using the Fugene 6 transfection reagent. All 
constructs were made using the PGL3 firefly-luciferase reporter plasmid. Cells 
on the plates were lysed at the indicated times by firstly removing media, 
washing with PBS and adding 50µl of luclite lysis buffer together with 50 µl 
PBS in each well. The SteadyLitePlus, High Sensitivity Luminesence Reporter 
gene assay system (Perkin Elmer) was used according to the manufacturer’s 
instructions. This system can easily assay the activity of two individual 
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reported enzymes (the firefly and Renilla luciferases) within a single system. 
The firefly luciferase reporter is measured first by adding Luciferase assay 
reagent I and after quantifying it, this reaction is quenched and the Renilla 
luciferase reaction is initiated with the addition of celenterazine 
(LuxBiotechnology). Measurement of the luciferase activity is done using a 
plate reading luminometer. Values from the firefly luciferase activity were 
normalized by the Renilla values and results were represented as graphs 
created in Microsoft Excel.  
 
 
2.14 RNA interference 
 
RNA interference (RNAi) is a post-transcriptional method leading to the 
silencing of genes. In this study, genes were knocked down using the 
SMARTpool TM Product Insert-Version 2.0 (DHARMACON, RNA 
technologies). Oligofectamine (Invitrogen LT) was used as the transfection 
reagent. 300,000 cells per well of a 6-well plate, were plated 24 hours prior 
transfection was performed. For each well 70µl of OPTIMEM is mixed with 5µl 
oligofectamine and incubated at room temperature for 10min. This solution is 
then mixed with 258µl Optimem and 7.5µl (50nM final concentration) siRNA 
oligos specific for each gene. After 25 min incubation, 160µl OPTIMEM is 
added to each one of them, reaching a final volume of 500µl, which is then 
added to the wells that have been previously washed with PBS. The final 
concentration of siRNA oligos in each well is 50nM. After 4hours of incubation 
2ml of DMEM 10% FCS is added to each well. 
 
80 
As a control reaction for the experiment, cells are subjected to transfection 
with the 1x Universal Buffer (Mock) (without any siRNA added), in order to 
detect cellular effects caused by the transfection event or delivery process. 
Another control used is the transfection with a non-functional, non-targeting 
siRNA in order to detect off-target effects caused by the introduction of any 
siRNA. These siRNAs have an impaired ability to be processed by RISC and 
share little or no homology with known mRNA targets in the cell. It is a more 
biologically relevant control than the Mock transfection control, as non-
targetings siRNAs are expected to have similar properties such as charge 
density and molecular weight. Their effects in the cell, if any, may be through 
non-RNAi pathways and for this reason may be used to check for general side 
effects associated with siRNA delivery. 
 
The SMARTpool siRNAs used were: siFoxM1 (M-009762-00), siHDAC2 (M-
003495-02), siFOXO3a (L-00307-00), siFOXA1 (L-010319-00) 
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2.15. Chromatin Immunoprecipitation (ChIP) 
 
ChIP is an important tool for identifying proteins, including histone proteins 
and non-histone proteins, associated with specific regions of the genome by 
using specific antibodies that recognize a specific protein or a specific 
modification of a protein. The initial step of ChIP is the cross-linking of protein-
DNA in live cells with formaldehyde. After cross-linking, the cells are lysed 
and crude extracts are sonicated to shear the DNA. Proteins together with 
cross-linked DNA are subsequently immunoprecipitated. Protein-DNA cross-
links in the immunoprecipitated material are then reversed and the DNA 
fragments are purified and PCR amplified.  
 
The cells used for the ChIP experiments were cultured and treated with the 
usual method stated above, in 10ml plates. When the cells were about 90% 
confluent, they were crosslinked for 10 minutes at 37 C with 36.5% 
fomaldehyde adjusted to a 1% final concentration (Sigma F8775). After being 
washed with cold PBS, the cells were sonicated in four 10-second pulses at 
maximum power in 300 µl of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCl [pH 8.1], 1 mM phenylmethyl sulfonyl fluoride, 1x protease inhibitor 
cocktail [Roche]). The supernatant was cleared by centrifugation at 13,000 x g 
at 4 C and further diluted with Buffer D, of which 1/6 was retained at -80 C as 
input control. DNA shearing produced DNA fragements of about 200 to 400 
bp. To preclear the chromatin solution, 2 µg of sonicated single-strand herring 
sperm DNA (Sigma), rabbit IgG (1:1000) and 45 µl of a 50% (vol/vol) slurry of 
protein G-Sepharose (Sigma) beads were added to the rest of the sample. 
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After incubation with rotation for 2 hours at 4 C, the beads were removed by 
centrifugation at 5000 rpm for 1 minute at room temperature in a bench top 
centrifuge, and the supernatant was collected. The retrieved supernatant was 
incubated with the antibody of interest overnight at 4 C (Table 2.7). The 
sample was then incubated with rotation in the presence of 2 µg of sonicated 
single-strand herring sperm DNA (Sigma) and 45 µl of a 50% (vol/vol) slurry of 
protein G-Sepharose (Sigma) beads. The beads were then washed 
sequentially with PBS, Tris-SDS-EDTA buffer (TSE) I, TSE II, TSE III, PBS 
and EDTA. The immunoprecipitated DNA (or the input control) was extracted 
with 300 µl of extraction solution (1% SDS and 1.1 M NaHCO3), incubated at 
65°C overnight to reverse the cross-links, and purified with the QIAquick PCR 
purification kit (Qiagen) according to the manufacturer's protocol. PCRs were 
then performed on the purified DNA using the primers stated below (Table 
2.8.). Analysis of the PCR products was performed on a standard 2% (wt/vol) 
agarose gel by electrophoresis in Tris-acetate-EDTA buffer, using a 100bp 
molecular marker.   
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ChIP Antibody Company 
FOXM1 (c-20) rabbit polyclonal 
IgG 
Santa Cruz Biotechnology 
FOXO3a /FKHRL1 (H144) 
rabbit polyclonal IgG 
Santa Cruz Biotechnology 
ERα (F-10) mouse monoclonal 
IgG 
Santa Cruz Biotechnology 
FOXA1 (Ab23738) rabbit 
polyclonal IgG 
Abcam 
HDAC2 (Ab7029-50) rabbit 
polyclonal 
Abcam 
H3K9 (9671)  rabbit polyclonal Cell Signalling 
H4K16 (sc-8662) goat 
polyclonal 
Santa Cruz Biotechnology 
 
Table 2.7. List of antibodies used in ChIP 
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Primer Sequence 
FOXO3a-VEGFpro Forward 5’-TCCGGGTTTTATCCCTCTTC-3’ 
Reverse 5’-TCTGCTGGTTTCCAAAATCC-3’ 
FOXA1-FOXC2pro Forward 5’-GTGTCTCACTCCTTCAGGGAAAGT-3’ 
Reverse 5’-AGCGACTTGGATCTCCTTCAAG-3’ 
 
Table 2.8. List of primers used for the PCR in ChIP. 
 
 
 
 
2.16 PCR  
 
PCR amplification was performed using a Taq DNA polymerase Kit (Qiagen). 
Reaction solutions contained 3µl DNA template, 0.5µl of forward primer 
(20µM), 0.5µl reverse primer (20µM), 1x PCR buffer, 1x Q solution, 0.2nM 
dNTP , 0.5 Taq polymerase and dH20 to a final volume of 50 µl. The PCR was 
carried out using a Gene Amp® PCR system 9700 (Applied Biosystems) using 
the following  program:  
 
A denaturation step for 1 min at 94 oC, annealing for 1-2 min at 55-65oC 
according to the oligonucleotides utilised, extension at 72oC for 1 min for 33 
cycles followed by a final extension for 10 min at 72 oC.  
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2.17 Biotiniylated oligo pull down 
 
Biotiniylated oligoucleotides were coupled to streptavidin beads in a solution 
containing 100µl PBS, 10µl FCS, 20µl of a 50% slurry of streptavidin-agarose 
beads (Sigma) and 1µl of annealed biotiniylated oligonucleotide. Beads were 
left to incubate with the oligos while rotating on a rotary wheel for 2 hours at 
room temperature. Following incubation, the oligo-coupled beads were spun 
down a 12000rpm on a bench top centrifuge for 2 minutes. The supernatant 
was discarded and 50mg of nuclear lysate was diluted in 2x volumes of low 
salt and added to each of biotiniylated oligo-coupled beads along with 1mg of 
sheared salmon sperm DNA and competitor non-biotiniylated double stranded 
oligonucleotides containing a wild-type, high affinity or mutant consensus site 
for prospective binding proteins. Samples were left mixing in a rotary wheel at 
4o C for 1 hour and subsequently incubated in at 30o C for 10 minutes. The 
beads were then washed 6 times in PBS containing protease inhibitors. 
 
Beads were separated from the washing buffer by centrifugation for 2 minutes 
at 3000 rpm and boiled in 20µl of 2x SDS-PAGE loading buffer for 10 minutes 
at 100o C. The samples were then loaded in an SDS-PAGE gel and the 
prospective binding proteins detected by western blotting. 
 
The sequences of oligonucleotides used for pull down assays are as following 
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WTFOXO3AF 
Biotin 
Biotin-
GTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTAAA 
MTFOXO3AF 
Biotin 
Biotin-
GTTTTATCCCTGTTCTTTTTTCTTGGGCATTTTTTAAA 
MTFOXO3A F GTTTTATCCCTCTTCTTTTTTCTTGGGCATTTTTTAAA 
WTFOXO3A F GTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTAAA 
WTFOXO3A R TTTAAAAAAAATGTTTAAGAAAAAAGAAGAGGGAT 
MTFOXO3A R TTTAAAAAAAATGCCCAAGAAAAAAGAAGAGGGAT 
WTFOXA1 F Biotin Biotin- TTCGTCCACAAATAAACAAAC 
WTFOXA1 F TTCGTCCACAAATAAACAAAC 
WTFOXA1 R TTGTGGACTGATTATTTATTC 
MTFOXA1 F Biotin Biotin- TCAGTCCACGGGTGGGCGGGC 
MTFOXA1 F TCAGTCCACGGGTGGGCGGGC 
MTFOXA1 R GCCCGCCCACCGTGGACTGA 
 
Table 2.9. List of biotin- and non- labeled primers used for the 
biotiniiylated oligo pulldown assay. 
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2.18 Nuclear-cytoplasmic fractionation. 
 
Cells were harvested with trypsin-EDTA and then centrifuged at 1200 rpm for 
5 minutes.  After washing the cell pellets with PBS they were transfered into 
1.5 ml eppendorf tubes and pelleted by centrifugation at 5000rpm for 2-3 
minutes in a bench top centrifuge at 4o C.    
 
CER I (NE-PER Thermo) was added to the cell pellet. Vortexing was followed 
for 15 seconds to fully suspend the cell pellet. The tubes were left on ice for 
10 minutes and afterwatrds CER II (NE-PER Thermo) was added to the 
tubes. The tubes were then vortexed for 5 seconds on the highest setting, left 
to incubate on ice for 1 minute and then vortexed again for 5 seconds on the 
highest setting. The cytoplasmic extract was collected after centrifugation of 
the tubes for 5 minutes at maximum speed in a bench top centrifuge at 4o C. 
The remaining pellet was then suspended in NER (NE-PER Thermo) and 
vortexed on the highest setting for 15 seconds. The samples were kept on ice 
and were vortexed four times, for 15 seconds, every 10 minutes. At the end 
the tubes were centrifuged at maximum speed in a bench top centrifuge for 10 
minutes at 4o C in order to collect the cytoplasmic extract. 
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2.19 Production of recombinant vector  
 
The cDNA of FOXA1 was cloned into a pCDNA3.1 (Promega) vector. The 
cDNA of FOXA1 was selected by PCR from MCF-7 cells, as described above 
and the product ran in a 1.5 % (w/v) agarose gel made up with 1x Tris-acetate 
buffer (40mM Tris-acetate, 1mM EDTA, pH 8.0) plus 1 µg of ethidium 
bromide. Samples were electrophorised by applying a constant current (100V) 
through the gel. cDNA fragments were visualised using a UV transilluminator. 
The cDNA fragment from the gel was cut out using a razor blade and used for 
subsequent purification. 
 
 
Extraction of DNA from agarose gel  
 
The cDNA fragment that was cut for the agarose gel was purified using the 
QIAquick Gel Extraction Kit (Qiagen), according to the manufacturer’s 
instructions. The gel fragment was dissolved by adding 3 volumes (per weight 
of gel slice) of QG buffer (QIAquick spin kit, Qiagen) and incubating at 50ºC 
for 10 minutes. The sample was then transferred to a QIAquick spin column 
and centrifuged for 1 minute after which the DNA in the column was washed 
with 0.75ml of PE buffer (QIAquick spin kit, Qiagen). Residual wash buffer 
was removed by centrifugation for 1 minute at full speed. DNA was eluted in a 
microcentrifuge tube by adding 30µl of ddH2O and centrifugation for 1 minute. 
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Ligation 
 
Ligation of the cDNA fragment with the pCDNA3 vector was performed using 
T4 DNA ligase. The ligation reaction included 1.0µl 10x T4 DNA ligase buffer 
(1x = 50mM Tris-HCl,10mM MgCl2, 10mM DTT, 1mM ATP, 25µg/ml BSA, pH 
7.5), 1.0µl T4 DNA ligase, 1:3 vector/DNA ratio and dH20 to a final volume of 
10µl. For a control reaction another sample was prepared containing the 
vector without the T4 ligase. Samples were incubated in water at 4oC 
overnight. 
 
 
2.20 Plasmids  
 
For the generation of human VEGF promoter constructs, a 1741 bp VEGF 
promoter construct was generated using PCR primers 5′- 
ATCTCGAGGAGGCTATGCCAGCTGTAGG-3′ and 5′-
GCAAGCTTTCTGCTGGTTTCCAAAATCC-3′ from genomic DNA and cloned 
into the pGL3 basic vector (Promega, Southampton, United Kingdom).  
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Figure 2.1 The 1741 bp VEGF promoter construct was cloned into a 
pGL3Basic vector between the XhoI and HindIII restriction enzyme sites. 
 
The HDAC2WT and HDAC2C262A/C274A expression plasmids were kind gifts from 
Dr. Antonella Riccio (University College London, UK) and the FOXO3a(A3) or 
FOXM1(ΔN) expression vectors have previously been described (Kwok et al.,, 
2008). 
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2.21 Site-specific mutagenesis 
 
Mutagenesis of the possible two forkhead binding sites of the VEGF promoter 
cloned into a pGL3-Basic-Luc vector was carried out by using the 
Quickchange Site-directed mutagenesis kit (Stratagene). Sample reactions 
were prepare in a total volume of 50 µl containing: 5 µl of 10x reaction buffer 
(Stratagene), 50ng of double stranded plasmid DNA, 125 ng of each primer, 
1µl of 25 mM dNTPs (Stratagene), 1µl of Pfu turbo DNA polymerase and 
ddH2O. 
 
 
2.22 Measurement of human VEGF by ELISA 
 
VEGF concentrations were measured by  a quantitative sandwich enzyme 
immunoassay (Quantikine ELISA R&D). Microplates were pre-coated with a 
specific VEGF monoclonal antibody and upon use 50 µl of assay diluent 
RD1W were added to the wells. 200 µl of either cell culture supernate 
samples or standards were loaded in triplicates to the wells and were left to 
incubate in room temperature in order for VEGF to bind to the immoblised 
antibody. After washing four times with 400 µl of washing buffer, 200 µl of 
VEGF conjugate (an enzyme-linked VEGF polyclonal antibody solution) were 
added to the wells. The plates were left to incubate for 2 hours in room 
temperature. Following washing, 200 µl substrate solution were added to the 
wells and colour was developed.  After 20 minutes of incubation, 50 µl  of top 
solution were added. The colour change was then stopped and its optical 
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density was measured at 450nm (Sunrise-Tecan) within 30 minutes (Sunrise-
Tecan). 
 
 
 
 
2.23 Co-Immunoprecipitation 
 
Co-immunoprecipitation (Co-IP) was performed to detect protein-protein 
interactions. Adherent cells were plated and treated according to the 
experimental procedure. The proteins were extracted using a Co-IP lysis 
buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 2 mM EDTA, 10% glycerol (v/v),  
0.5% Triton-X (v/v), 10 mM NaF, 10 mM β-Glycerophosphate pH 7.3, 0.1 mM 
Na3VO4, 100 U/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF) which has 
a composition adequate to perform precipitation of the target protein and co- 
precipitation of binding partners / protein complexes. The lysates were pre-
cleared with agarose beads (15 µl per sample) for 30 minutes. After 
centrifugation at 0.4xg. for 20-40 seconds at 4 ˚C, the supernatant was 
transferred to another eppendorf tube. Protein concentration was then 
determined and 0.3-0.5 mg of protein extract were incubated with the antibody 
and beads for 2-3 hours, rotating at 4 ˚C. The antibodies used at this step 
were the same as the ones used for ChIP. Immunoprecipitates were then 
washed 3 times with the same lysis buffer (by centrifugation at 0.4 xg for 20-
40 seconds at 4 ˚C) and boiled for 5 minutes with Laemmli buffer before 
separation on a SDS-PAGE gel.  
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2.24 Statistical analysis 
 
To test for the relationship between VEGF, FOXM1 and nuclear/cytoplasmic 
FOXO3a, statistical analysis was performed using Pearson’s correlation test 
and was considered significant at p<0.05. All statistical analysis was 
performed with SPSS v.16 (SPSS inc, Chicago, IL, USA).    
 
2.25 Wound healing scratch assay 
 
This assay was done to observe the migration of breast cancer cells . 
The cells were plated out on 6 cm dishes and left to grow ( 10% CO2 at 37o C) 
in a confluency of about 90%. Cell were growing in serum starved conditions 
overnight. The scratch was made using a sterile 2 µl pipette tip and 
photographed after 24 h.  
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RESULTS 
 
3.  THE ROLE OF FOXO3a AND FOXM1 IN THE REGULATION 
OF VEGF AND CELL MIGRATION IN BREAST CANCER. 
 
 
3.1 BACKGROUND AND OBJECTIVES OF CHAPTER 3. 
 
 
The Forkhead box class O (FOXO) transcription factors are crucial 
downstream effectors of the PI3K-Akt signalling pathway.  Deregulation of 
FOXO proteins is associated with tumorigenesis and cancer progression. 
Interestingly, emerging evidence has demonstrated that FOXO proteins, in 
particular the FOXO3a, has a central role in mediating the cytostatic and 
cytotoxic effects of chemotherapy (Gomes, 2008; Fernandez de Mattos, 2008; 
Myatt, 2007; Fernandez de Mattos, 2004; McGovern, 2009).  
 
VEGF plays a crucial role in tissue development and maintenance through 
regulating the processes of vasculogenesis, angiogenesis and 
lymphangiogenesis (Lohela et al.,, 2009). Upon ligand-binding, the VEGF 
receptors activate downstream signalling cascades, including the 
phosphatidylinositol 3-kinase(PI3K)-Akt(PKB), which controls the endothelial 
cell survival, proliferation and migration. VEGF and its receptors are 
frequently overexpressed in human tumours, especially in breast, non-small 
cell lung, colorectal, and prostate cancers (Jain et al.,, 2009). In consequence, 
VEGF and associated signalling pathways, such as the PI3K-Akt pathway 
which FOXOs are involved, have been the targets for many novel anti-cancer 
targeted therapeutics (Margolin, 2002).  
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A recent cDNA microarray study revealed that FOXO3a can potentially 
repress VEGF expression in a colon carcinoma cell line (Delpuech et al., 
2007). In the present study, we went on to investigate the molecular 
mechanism by which FOXO3a represses VEGF expression. 
 
 
3.2 RESULTS OF CHAPTER 3 
 
 
 
3.2.1 The activation of FOXO3a in response to Lapatinib in HER2/neu + 
cells is associated to VEGF repression. 
 
In order to investigate the effect of Lapatinib in the regulation of VEGF 
expression, the HER2/neu + breast cancer cell lines BT474 and SKBR3 were 
used.  As it has been previously reported in our laboratory, the tyrosine kinase 
inhibitor Lapatinib is affecting the expression of FOXO3a causing its 
upregulation and activation  in HER2/neu + cells. It would be interesting to 
know if this effect could be coupled to a possible VEGF response.  
 
For this purpose, the two Lapatinib sensitive (HER2/neu+) cell lines 
mentioned above and one non-sensitive (HER2/neu-), MDA-MB-231, breast 
cancer cell line, were used. All were treated with 1 µM Lapatinib and 
harvested at different time points of 0, 4, 8, 24 and 48 hours.  It was shown by 
western blotting that the effect of Lapatinib in the expression of FOXO3a, 
FOXM1 and VEGF is crucial when compared to the non-sensitive cell line. 
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At 4 hours of Lapatinib treatment, the sensitive BT474 cells showed a 
decrease in the expression of VEGF which is coupled to a decrease in the 
phosphorylated FOXO3a and FOXM1 expression levels. The levels of total 
FOXO3a though were up-regulated, suggesting the time-dependent increase 
of FOXO3a in the nucleus where it translocates upon its dephosphorylation. 
This activation of FOXO3a was suggested to be responsible for the further 
expressional status of FOXM1 and VEGF (Fig. 3.1).  
 
Notably, all factors were down-regulated in BT474 cells after 48 h, probably 
reflecting global protein degradation and cell death. In contrast, there were no 
appreciable changes in P-FOXO3a, total FOXO3a, FOXM1, or VEGF levels 
upon treatment of Lapatinib-resistant MDA-MB-231 breast cancer cells.  
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Figure 3.1. FOXO3a activation correlates with down-regulation of FOXM1 
and VEGF expression. The (HER2/neu+) BT474 and SKBR3 and the 
(HER2/neu-) MDA-MB-231 cell lines were plated out on 6 cm dishes, treated 
with 1 µM Lapatinib and harvested at 0,4,8,24 and 48 h time points. Cell 
lysates were separated by SDS-PAGE and immunoblot analysis was done 
using the indicated antibodies Immunoblotting against Tubulin was used to 
ensure efficient loading. 
 
 
 
To confirm that Lapatinib represses VEGF expression, secreted levels of 
VEGF were determined by ELISA in the three cell lines (Fig. 3.2). Whereas 
secreted VEGF levels remained unchanged upon Lapatinib treatment of 
MDA-MB-231 cells, the levels declined markedly after 24 h treatment of the 
sensitive BT474 and SKBR3 cells (50% decrease in 24 hours of treatment). 
The same type of results, occurred in the transcriptional levels of VEGF, 
which were quantified by RTqPCR and as expected, were down-regulated 
earlier, by 8 hours of treatment. A significant decrease in FOXM1 
transcriptional levels was observed, which could be playing a crucial role to 
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the down-regulated phenotype of VEGF. Notably, FOXO3a transcript levels 
were also up-regulated in SKBR3 cells (Fig 3.3).  
 
Together these results demonstrate that Lapatinib treatment of sensitive 
breast cancer cells induces and activates FOXO3a but inhibits FOXM1 and 
VEGF expression. 
 
 
 
 
 
Figure 3.2. Lapatinib treatment of sensitive breast cancer cells inhibits 
VEGF expression. The (HER2/neu+) BT474 and SKBR3 and the 
(HER2/neu-) MDA-MB-231 cell lines were plated out on 6 cm dishes, treated 
with 1 µM Lapatinib where their supernatant was collected at 0,8, and 24 h 
time points. VEGF concentration was measured with a human VEGF-ELISA 
kit.  
 
The transcriptional levels of VEGF did not show any significant change, and 
as with the secreted VEGF levels, only a small increase of VEGF mRNA was 
observed. Together with this data, FOXO3a and FOXM1 mRNA levels were 
unaltered to the addition of Lapatinib in the growing environment of the cells 
(Fig. 3.3). 
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 Figure 3.3. Lapatinib inhibits VEGF and FOXM1 mRNA expression in the 
sensitive SKBR3 and BT474 but not the resistant MDA-MB-231 cells. 
Both the sensitive and resistant cell lines were plated out on 6 cm dishes, 
treated with µM Lapatinib  at 0, 8 and 24 h time points. They were harvested 
for RNA extraction followed by cDNA synthesis. The mRNA levels of VEGF, 
FOXM1 and FOXO3a were quantified by RTqPCR and normalized by L19. 
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3.2.2 FOXO3a represses VEGF and FOXM1 expression  
 
To study the mechanism underlying the reciprocal relationship between 
FOXO3a activation and VEGF and FOXM1 inhibition, we used an estrogen 
receptor α (ER)-negative MDA-MB-231 cell line expressing a fusion protein 
containing a constitutively active FOXO3a(A3) and ligand-binding domain of 
ER. In MDA-MB-231-FOXO3a(A3):ER cells, FOXO3a can be conditionally 
activated by 4-hydroxytamoxifen (4-OHT).  
 
Upon 8 hours of 4-OHT treatment, FOXO3a presence in the cell nucleus was 
increased. This increase was followed by the down-regulation of VEGF 
expression, both secreted and nuclear, at 8 hours onwards (Fig 3.4A). It was 
also followed by the decrease of FOXM1 at transcriptional  (Fig. 3.4B) and 
translational level (Fig. 3.4A). The mRNA levels of VEGF showed a small 
decrease, a fact which was more notably significant when compared to the 
non-induced control MDA-MB-231 cells in which the mRNA levels of VEGF 
were increased with time (Fig 3.4B). 
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A) 
 
 
      B) 
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        C) 
 
 
 
Figure 3.4. Active FOXO3a down-regulates VEGF expression and VEGF 
and FOXM1 transcription. A)  MDA-MB-231-FOXO3a (A3) inducible and 
control MDA-MB-231 cells were plated out on 6 cm dishes and after 4-OHT 
treatment  for the activation of FOXO3a, were harvested at 0, 4, 8, 24, 48 h 
time points. Nuclear fractions were prepared with the NE-PER Thermo kit as 
described in the material and methods section. Cell lysates were separated by 
SDS-PAGE and immunoblot analysis was done using the FOXO3a, FOXM1 
and VEGF antibodies Immunoblots against Lamin B (nuclear) served to 
ensure efficient cellular fractionation. B)  The same cell lines were plated out 
on 6 cm dishes, treated with 4-OHT and after 0, 8, 24, 48 h their supernatant 
was collected for secreted VEGF quantification by ELISA. The results were 
read at 450 nm. C) The cell lines mentioned above were plated out on 6 cm 
dishes , treated with 4-OHT and harvested at 0, 8, 24 h for RNA extraction 
followed by cDNA synthesis and mRNA quantification by RTqPCR. The 
results were normalised by L19. Statistical analysis was performed using 
Pearson’s correlation test. 
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3.2.3 FOXO3a-dependent regulation of VEGF expression. 
 
To assess furthermore the effect of FOXO3a in the regulation of VEGF 
expression, the constitutively active FOXO3a (A3)-pCDNA3.1 expression 
vector was transfected and was overexpressed in MCF-7 cells. The effect of 
this overexpression was a very significant decrease of VEGF expression, 
together with an, as well, very significant decrease in the expression of 
FOXM1 (Fig. 3.5A). 
 
Consistent with these results, the mRNA levels of VEGF were increased upon 
the silencing of FOXO3a in the same cell line (Fig 3.5B). Together with the 
mRNA levels, the expression of FOXM1 and VEGF was observed to be 
affected by the silencing of FOXO3a. In the absence of FOXO3a in MCF7 
cells, FOXM1 expression seems to be upregulated and VEGF expression 
(Fig.3.6) as well.  
 
Clearly, these experiments give an insight to the FOXO3a- and FOXM1-
dependent regulation of VEGF and the dependence of these two forkhead 
transcription factors in the regulation of each other. 
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A)                                  B) 
 
 
Figure 3.5. Active FOXO3a overexpression causes the down-regulation 
of FOXM1 and VEGF protein and mRNA levels in MCF-7 cells. A) MCF-7 
cells grew on 6 cm dishes and harvested at 48 h after transfection with the 
FOXO3a(A3)-pcDNA3.1 expression vector. The cells were transfected using 
oligofectamine. Protein quantification was done after cell lysis followed by 
western blotting. Tubulin was used as a loading control. B) The cells were 
harvested at 24 h after transfection with the FOXO3a(A3)-pcDNA3.1 
expression vector. RNA extraction was followed by cDNA synthesis and 
mRNA quantification by RTqPCR. The results were normalized by L19. 
Statistical analysis was performed using Pearson’s correlation test. 
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      A)                                            B) 
 
 
Figure 3.6. FOXO3a silencing is coupled to a FOXM1 and VEGF up-
regulation in MCF-7 cells. A) MCF-7 cells were plated in a 6-well plate, 
transfected with FOXO3a siRNA using oligofectamine, harvested after 48 h 
and lysed. Proteins were separated by SDS-PAGE and immunoblot analysis 
was done using the indicated antibodies Immunoblotting against Tubulin was 
used to ensure efficient loading. Non specific (control) siRNA was used to 
ensure targeted silencing efficiency. B) MCF-7 cells were plated and 
transfected as above and harvested at 24 h. RNA extraction, cDNA synthesis 
and subsequently RTqPCR was done for the measuring of mRNA of VEGF 
and FOXM1 respectively. L19 was used to normalise the results. Statistical 
analysis was performed using Pearson’s correlation test. 
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3.2.4 FOXO3a and FOXM1 modulate VEGF promoter activity. 
 
We postulated that FOXO3a could suppress VEGF transcription, either by 
modulating promoter activity or, indirectly, by inhibiting FOXM1 expression. To 
differentiate between these scenarios, a 1741 bp region of the putative VEGF 
promoter, representing positions -1,926 to -186 relative to the predominant 5’-
transcription start site, was cloned upstream of a luciferase reporter . Co-
transfection studies showed that expression of the FOXO3a(A3) mutant 
represses the activity from the putative VEGF promoter whereas exogenous 
expression of  FOXM1 transactivated the reporter construct in a dose-
dependent manner (Fig. 3.7). Sequence analysis identified 2 consensus 
forkhead transcription response elements (FHREs) in the proximal promoter 
region. Mutation of the distal (-319) but not the proximal (-178) FHRE 
abrogated the ability of FOXO3a(A3) and FOXM1 to inhibit and activate, 
respectively, this promoter-reporter construct. Thus, a single response 
element, designated FHRE2, appears to mediate the effects of both 
transcription factors on the VEGF promoter.  
 
 
 
 
 
107 
 
 
Figure 3.7. The promoter activity of wt VEGF is suppressed by active 
FOXO3a and increased by active FOXM1 via FHRE2 . MCF-7 cells were 
plated out in 96 well plates and transiently transfected with 10 ng of the 
VEGFwt-pGL3b, VEGFmut1-pGL3b and VEGFmut2-pGL3b promoter/reporter 
constructs respectively. The expression vectors of the active FOXO3A(A3)-
pCDNA3.1 and active FOXM1 (ΔΝ)  respectively were transfected in MCF-7 
cells, in titrations of 0, 5, 10 and 20 ng harvested after 16 h and assayed for 
luciferase activity. The VEGF-pGL3b mutated promoter/reporter constructs 
were formed by site-directed mutagenesis, described in the material and 
methods section. 
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3.2.5 FOXO3a antagonises FOXM1 by direct binding at the FHRE binding 
area of the VEGF promoter. 
 
In order to test further the direct binding of FOXO3a on the FHREs mentioned 
above, chromatin immunoprecipitation (ChIP) followed. Indeed, it was 
revealed that FOXO3a is recruited onto the promoter of VEGF. 
 
To determine the mode of action of the two forkhead transciption factors, 
FOXO3a and FOXM1, on their binding on the VEGF promoter, we used two 
types of assessment. First, BT474 cells were treated with Lapatinib for 2 and 
4 hours and immunoprecipitated with the FOXM1 and FOXO3a. We observed 
that FOXM1 is recruited in non-treated cells on the promoter whereas 
FOXO3a is not. However, post-treated cells exhibit a different binding status, 
at 2 hours of Lapatinib treatment, with FOXO3a antagonizing FOXM1 and 
taking its place on the FHRE binding area of the VEGF promoter (Fig. 3.8). 
Notably, the binding of both the FOXO3a and FOXM1 to the VEGF promoter 
decreased substantially by 4 h, probably suggesting decreased accessibility 
to the proximal region of the VEGF promoter (Fig. 3.8). Secondly, to test the 
consistency of this regulation, the MDA-MB-231 FOXO3a:ERa cell line was 
used for ChIP. 
 
Again, in those cells, FOXM1 is antagonised by FOXO3a in the FHRE binding 
area of the VEGF promoter (Fig. 3.8). Only this time the effect is not as fast as 
by treating cells with Lapatinib. 
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Figure 3.8. FOXO3a is recruited to the proximal region of the VEGF 
promoter in vivo. MDA-MB-231-FOXO3a:ER inducible cells were treated 
with 4-OHT and were cross-linked using formaldehyde in vivo. Chromatin 
fragments were subjected to immunoprecipitation with antibodies against IgG 
(non-specific) , FOXO3a or FOXM1. Afterwards, the cross-linking was 
reversed and the immunoprecipitated DNA was amplified by PCR with 
primers (-319 to -186) for the indicated region of VEGF’s promoter. It was 
then resolved in a 2% agarose gel and photographed under UV. The same 
procedure was applied at BT474 cells treated with 1µΜ Lapatinib. 
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To examine furthermore the mechanism by which FOXO3a and FOXM1 
regulates the VEGF promoter, we performed oligonucleotide pull-down assay 
with nuclear lysates from unstimulated MDA-MB-231-FOXO3a(A3):ER and 
MDA-MB-231 cells or cells treated with 4-OHT for 8 and 24 h. Western blot 
analysis of the pulled-down complexes showed that both FOXO3a and 
FOXM1 bind to the wild-type FHRE2 of VEGF, but not the mutated FHRE2 
site (Fig. 3.9). The binding of FOXO3a and FOXM1 to the FHRE2 could be 
competed off by excess amounts of the wild-type but not mutated FHRE2 
oligonucleotides, indicating that both transcription factors bind directly to this 
response element (Fig. 3.9A). The results also revealed that FOXM1 is 
constitutively bound to FHRE2 in untreated MDA-MB-231-FOXO3a(A3):ER 
and the MDA-MB-231 cells. However, FOXM1 was replaced by the 
FOXO3a(A3):ER in response to 4-OHT stimulation of MDA-MB-231-
FOXO3a(A3):ER but not of MDA-MB-231 cells, suggesting that activated 
FOXO3a down-regulates VEGF expression by competitive displacing FOXM1 
bound to FHRE2.  
 
The FHRE pull-down experiment was then repeated in the BT474 cells 
following lapatinib treatment in the presence of molar excess of mutated 
FHRE oligonucleotides (Fig. 3.9B). Parallel Western blot analysis of nuclear 
and cytoplasmic lysates showed that lapatinib induces nuclear accumulation 
of FOXO3a after 2 to 4 hours, concomitant with the down-regulation of VEGF 
expression but without discernible change in FOXM1 levels at these time-
points (Fig. 3.9C). The pull-down results, however, indicated that the lapatinib-
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activated FOXO3a displaces FOXM1 from the FHRE2 of the VEGF promoter 
at these time-points. Thus, although prolonged activation of FOXO3a will 
down-regulate FOXM1 levels, inhibition of VEGF expression is an early event 
and mediated, at least in part, by displacing FOXM1 and binding to FHRE2. 
 
The above observations pointed to the possibility that FOXO3a play a role in 
recruiting chromatin remodelling enzymes, such as histone deacetylases 
(HDACs), to repress the VEGF transcription. 
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    A) 
 
   B)                                                                  C) 
 
 
 
 
Figure 3.9 FOXO3a and FOXM1 compete for binding to FHRE2. A) The 
MDA-MB-231-FOXO3aER cell line was induced with 4-OHT for 8 and 24h. 
The extracts were used for pull-down experiments using 
streptavidin/sepharose beads couples to biotin-conjucated oligos containing 
the proximal region of the VEGF promoter studied. The pulled down protein 
complexes were resolved by SDS-PAGE and immunoblotted against tha 
indicated antibodies. MDA-MB-231 cells served as a control. B) The same 
method was applied in BT474 Lapatinib-sensitive cells treated with 1µΜ 
Lapatinib for 2 and 4 h. C) Cellular fractionation was done in BT474 cells 
using the NE-PER Thermo kit in order to see the alterations of the proteins 
interested on, as the whole extracts (B) did not show any major differences. 
SP1 and Actin were used as loading controls of nuclear and cytoplasmic 
fractions respectively. 
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3.2.6 The increased expression of FOXO3a represses cell migration, in 
vitro. 
 
As FOXO3a seems to be a crucial factor for the transcriptional and 
translational status of VEGF, we were keen on studying the effect of up-
regulated FOXO3a expression on breast cancer cell migration. In order to 
examine this, wound healing assays were performed. Using the MDA-MB-231 
FOXO3a:ERa inducible system mentioned above, and the control cell line 
MDA-MB-231, we made a scratch on the cell monolayer and pictured it, at 0 
and 24 hours. For both the cell lines the supernatant applied on the cells was 
taken from the same cells pre-treated with 4-OHT before, so that, VEGF 
which is secreted by the cells, would be the sole factor affecting cell migration. 
The percentage of the wound healing was measured by the ratio of average 
decrease between the edges of the “wounded” cell monolayer. 
 
Although the control MDA-MB-231 cells managed to heal the wound well 
exhibiting healing of 75%, the MDA-MB-231 FOXO3a:ERa cells showed a 
very slow cell migration, healing just 20% of the wound (Fig. 3.10). This 
decrease in cell migration highlights the importance of FOXO3a in the 
repression of VEGF and thus its character upon cell migration. 
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Figure 3.10 Breast cancer cells migrate at slower rates in scratch wound 
healing assays when cultured in supernatants derived from FOXO3a-
induced MDA-MB-231 cells. MDA-MB-231-FOXO3aER cells were plated out 
on 6cm dishes. When 90% confluent a scratch was done on the monolayer. 
Supernatant from 4-OHT treated cells was applied on them to grow with, in 
order to assess the effect of secreted VEGF on the cells. The wound healing 
was photographed after 24 h. The MDA-MB-231 was used as a control 
against the inducible cell line. 
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3.3 DISCUSSION 
 
 
Signals mediated through VEGFs and their receptors have been shown to be 
essential for breast cancer carcinogenesis, cell migration (metastasis) and 
angiogenesis. Yet, the molecular mechanisms regulating VEGF expression in 
cancer cells are only partially understood.   
 
Using the lapatinib sensitive breast cancer cell lines BT474 and SKBR3 as 
models for FOXO3a activation, the hypothesis that FOXO3a regulates VEGF 
expression was examined and the underlying mechanisms involved explored 
in the present study. Lapatinib treatment resulted in inactivation of the 
phosphatidylinositol-3-kinase (PI-3K) pathway, nuclear translocation and 
activation of FOXO3a (Francis, 2009) and ultimately reduction in VEGF 
expression at protein, mRNA and gene promoter levels. Transient transfection 
and inducible FOXO3a expression experiments showed that FOXO3a 
represses while FOXM1 activates VEGF expression through a proximal FHRE 
site of the VEGF promoter, as mutation of this FHRE abrogated the regulation 
by FOXO3a and FOXM1. ChIP and oligonucleotide pull-down assays further 
demonstrated that both FOXO3a and FOXM1 bind directly to the FHRE of the 
VEGF promoter and that activated FOXO3a can displace FOXM1 from the 
FHRE, suggesting that FOXO3a can repress VEGF expression through 
competing off the transcriptional activator FOXM1. Consistently, FOXO3a 
accumulated and replaced FOXM1 at the FHRE as early as 2 h after lapatinib 
treatment; however, it was also noted that neither FOXO3a nor FOXM1 bound 
to the FHRE by 4 h. The lack of occupancy of the proximal VEGF promoter 
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region by FOXO3a and FOXM1 at 4 h suggested that FOXO3a accumulation 
might lead to exclusion of transcription factors through chromatin remodelling.  
Overexpression of FOXM1 has been implicated with metastasis and 
angiogenesis in a number of malignancies, including glioma, gastric and 
pancreatic cancer. Consistent with our findings, a recent study has also 
demonstrated that FOXM1 transcriptionally regulates VEGF expression in 
glioma cells (Zhang, 2008). However, in the present study we further 
demonstrated that FOXM1 functions downstream of FOXO3a, and its activity 
and expression are negatively regulated by FOXO3a. The ability of FOXO 
proteins to repress VEGF expression has been documented in Foxo1 null 
cells where VEGF is overexpressed and angiogenesis deregulated (Park, 
2009; Furuyama, 2004).  
 
In summary, together the present results suggest that FOXO3a can potentially 
repress VEGF expression. Activated FOXO3a can compete off the 
transcription activator FOXM1 from binding to the FHRE of the VEGF gene 
promoter. Furthermore, FOXO3a has also been shown previously to be able 
to repress FOXM1 expression at transcriptional levels (Francis, 2009). 
Consequently, FOXO3a can repress VEGF expression indirectly via 
regulating FOXM1 expression. The mechanism by which FOXO3a represses 
VEGF expression may represent common means whereby FOXO3a 
negatively regulates target gene expression. Thus, the present study also 
provides novel understanding on the mechanisms by which FOXO 
transcription factors repress target gene expression. Furthermore, the findings 
from this study also suggest that therapeutic strategies targeting FOXO3a or 
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FOXM1 can be used as an alternative or in parallel with anti-VEGF targeted 
agents as well as conventional chemotherapy in rational and effective 
treatment of tumours.  
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4. THE ROLE OF FOXO3A IN THE RECRUITMENT OF HDAC2 
FOR THE REGULATION OF VEGF IN BREAST CANCER. 
 
4.1 BACKGROUND AND OBJECTIVES OF CHAPTER 4 
 
When HDACs deacetylate histones gene transcription is repressed due to the 
very compact chromatin structure where transcription factors and other 
complexes cannot access the DNA to promote gene transcription. HDACs 
interact with other molecules in order to regulate transcription and chromatin 
remodeling. In this chapter, the idea of HDACs being recruited by FOXO3a for 
the regulation of VEGF transciption is examined.   
 
HDAC inhibitors bind and inhibit HDACs, leaving an open chromatin structure 
where transcription factors and other elements can bind to the DNA and 
regulate gene transcription. The HDAC inhibitor TSA could be a powerful tool 
in the understanding of the transcriptional repression mechanism and the 
subsequent elucidation of the mode of action of FOXO3a and FOXM1 in the 
regulation of VEGF transcription via HDAC complexing. 
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4.2 RESULTS OF CHAPTER 4 
 
4.2.1 TSA affects the expression pattern of VEGF.  
 
To test the hypothesis that FOXO3a recruits HDACs to repress VEGF 
transcription, MCF-7 cells were treated with the HDAC inhibitor TSA and the 
expression of VEGF was monitored. RTqPCR analysis demonstrated that 
TSA strongly enhances mRNA levels of VEGF (Fig.4A). TSA, as expected, 
affected in the same manner, the expression pattern of VEGF. VEGF protein 
levels were increased upon inhibition of HDACs, and more specifically 
HDAC2  which was used in the experiments below. 
 
A)                                                      B) 
 
 
Figure 4.1 TSA treatment increases the transcriptional and translational 
levels of VEGF. A) MCF-7 cells were plated out on 6 cm dishes, treated with 
1µM TSA for 8 h and harvested for RNA extraction followed by cDNA 
synthesis. The mRNA levels of VEGF were quantified by RTqPCR and 
normalized by L19. B) MCF-7 cells were plated out on 6 cm dishes, treated 
with 1µM TSA for 12 h and harvested for protein extraction. Cell lysates were 
separated by SDS-PAGE and immunoblot analysis was done using the 
indicated antibodies Immunoblotting against Tubulin served to ensure efficient 
loading. 
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4.2.2 TSA alters the promoter activity of VEGF in a FKHR-dependent 
manner. 
 
TSA also triggered a marked induction in VEGF promoter activity, which was 
abolished upon mutation of the FHRE2, but not the FHRE1, site (Fig.4.2.A). 
This result showed that HDACs should be acting in collaboration with 
forkheads which act on the FHRE2 binding site of VEGF’s proximal promoter 
region. Conversely, overexpression of the dominantly active HDAC2C262A/C274A 
mutant, but not the wild-type HDAC2, repressed VEGF promoter activity in a 
dose-dependent manner (Fig.4.2.B)  
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Figure 4.2.  The promoter activity of VEGF depends on a correlation 
between HDACs and FKHR. MCF-7 cells were plated out in 96 well plates 
and transiently transfected with 10 ng of the VEGFwt-pGL3b, VEGFmut1-
pGL3b and VEGFmut2-pGL3b promoter/reporter constructs respectively. A) 
They were treated with 1 µM TSA for 8h, harvested after 16 h and assayed for 
luciferase activity, revealing a correlation between HDAC and FKHR for the 
VEGF promoter activity B) MCF-7 cells were treated with the same 
promoter/reporter constructs, in the same order, and either the dominantly 
active HDAC2C262A/C274A mutant or the wt HDAC2 expression vectors were 
titrated into the cells in 5,10, 20 ng doses.The cells were harvested after 16h 
and assayed for luciferase activity. The promoter of VEGF again confirmed an 
HDAC2-affected activity via the FKHR binding sites. 
 
 
 
This ability of HDAC2 to repress VEGF promoter activity was again 
dependent on a functional FHRE2. The inability of wild-type HDAC2 to 
repress VEGF promoter activity could be due to the high levels of 
endogenous HDAC2 in MCF-7 cells.  
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4.2.3  HDAC2 binds on the proximal VEGF promoter 
 
In order to examine in more detail the relation between HDAC2 and the FKHR 
bining sites on the proximal VEGF promoter area, ChIP assays were 
performed. The cells once more were treated with the HDAC inhibitor TSA 
and demonstrated that TSA induced a decrease in HDAC2 binding to the 
proximal VEGF promoter (Fig.4.3).  
 
 
 
Figure 4.3 ChIP revealed HDAC2 recruitment on FKHR binding site of the 
VEGF promoter. MCF-7 cells were treated with 1µM TSA for 4 h and were 
undergone formaldehyde cross-linking in vivo. Chromatin fragments were 
subjected to immunoprecipitation with antibodies against IgG (non-specific) or 
HDAC2. Afterwards, the cross-linking was reversed and the 
immunoprecipitated DNA was amplified by PCR with primers (-319 to -186) 
for the indicated region of VEGF’s promoter. It was then resolved in a 2% 
agarose gel and photographed under UV. 
 
 
 
 
 
 
 
 
 
 
 
123 
 
4.2.4 VEGF expression increases upon silencing of HDAC2 
 
 
Moreover HDAC2 was knocked down in MCF-7 cells using siRNA in order to 
test further the effects of HDAC2 on the expression of VEGF (Fig. 4.4).  The 
protein levels of VEGF were up-regulated significantly, indicating for one more 
time that HDAC2 plays a crucial role in the regulation of VEGF expression. 
 
 
 
Figure 4.4 HDAC2 silencing induces expression of VEGF. MCF-7 cells 
were plated out in a 6-well plate, transfected with siRNA against HDAC2 and 
harvested after 72 h. Lysates were analysed by SDS-PAGE and 
immunoblotted against HDAC2, VEGF and Tubulin antibodies. Tubulin was 
used as a loading control. 
 
 
 
 
4.2.5 FOXO3a interacts with HDAC2 on the VEGF promoter causing the 
deacetylation of histones 3 and 4 
 
To examine if FOXO3a complexes with HDAC2 upon FOXO3a activation, the 
sensitive BT474 cells treated with Lapatinib were used. HDAC2 and FOXO3a 
co-immunoprecipitated and this interaction was enhanced upon Lapatinib 
treatment, probably reflecting nuclear translocation of FOXO3a (Fig. 4.5).  
 
124 
 
 
 
Figure 4.5. HDAC2 and FOXO3a interact and this interaction is enhanced 
by FOXO3a activation. BT474 cells were plated out on 6 cm dishes and 
treated with 1 µΜ Lapatinib. After harvesting at 0, 2 and 4 h of drug treatment 
Whole cell extracts were prepared in lysis buffer and immunoprecipitations 
(IP) were performed using the FOXO3a and HDAC2 antibodies. The IP 
samples along with INPUT samples from the whole cell lysates were analysed 
by SDS-PAGE and immunoblotted with the HDAC2 and FOXO3a antibodies.  
 
 
 
To assess if the HDAC2-FOXO3a interaction complex is recruited, in vivo, on 
the proximal VEGF promoter on the area characterised from the previous 
experiments, ChIP was performed. ChIP assays showed increased 
recruitment of HDAC2 to the proximal VEGF promoter after 2 h of Lapatinib 
treatment. HDAC2 recruitment coincided with a decrease in bound acetylated 
histones H3 and H4, indicating active chromatin remodelling and compaction 
of the proximal VEGF promoter. Further, siRNA-mediated FOXO3a 
knockdown in BT474 cells abolished the recruitment of HDAC2 to the 
proximal VEGF promoter upon Lapatinib treatment as well as the concomitant 
decrease in acetylated histones H3 and H4. These findings demonstrate that 
FOXO3a activation in breast cancer cells results in displacement of DNA-
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bound FOXM1, binding to FHRE2, recruitment of HDAC2, and transcriptional 
repression of VEGF. 
 
 
 
Figure 4.6 HDAC2 is recruited on the proximal VEGF promoter causing 
deacetylation of H3 and H4 in vivo. BT474 cells were treated with 1µΜ 
Lapatinib and were formadehyde cross-linked in vivo. Chromatin fragments 
were immunoprecipitated with antibodies against IgG (non-specific) , HDAC2, 
acH3 or acH4. Afterwards, the cross-linking was reversed and the 
immunoprecipitated DNA was amplified by PCR with primers (-319 to -186) 
for the indicated region of the VEGF promoter. Afterwards, it was resolved in 
a 2% agarose gel and photographed under UV.  
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4.3 DISCUSSION 
 
 
As discussed in chapter 3, FOXO3a can repress VEGF, by antagonising 
FOXM1. It was shown that FOXO3a activation results in the recruitment and 
the subsequent removal of FOXM1 on a specific forkhead binding site of the 
proximal promoter of VEGF. However, still the potential mechanism of this 
repression was not elucidated. HDACs which are critical transcriptional 
regulators were studied and it was shown that HDAC2 is recruited on the 
VEGF promoter. Upon FOXO3a activation and its recruitment in the nucleus 
and the VEGF promoter, HDAC2 was also found to be recruited on the same 
area of the promoter. Additionaly HDAC2 complexes with FOXO3a when 
active. Thus, the recruitment of the HDAC2/FOXO3a on the functional 
forkhead binding site of the proximal is a crucial regulator of transcriptional 
regulation. Moreover, this binding on the promoter, causes the de-acetylation 
of hstones 3 and 4 suggesting chromatin remodeling.   
 
Concluding, the model proposed for VEGF transcriptional regulation in breast 
cancer cells when FOXO3a is activated, is that FOXO3a is recruited on the 
VEGF promoter in a complex with HDAC2 which causes the deacetylation 
and the condensation of chromatin. In this way other transcription factors, 
such as FOXM1 or other inducing factors of VEGF expression are unable to 
reach the regulatory binding site of VEGF and gene suppression is achieved. 
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Figure 4.7 FOXO3a complexed with HDAC2 is recruited on the proximal 
VEGF promoter causing deacetylation of H3 and H4 and subsequent 
chromatin condensation leading to VEGF repression of transcription. 
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5. THE REGULATION OF VEGF BY FOXA1 AND FOXC2 IN 
BREAST CANCER. 
 
5.1 BACKGROUND AND OBJECTIVES OF CHAPTER 5 
 
As we have seen from the previous chapters, two members of the family of 
the forkhead transcription factors emerged critical for the expression of VEGF 
and thus, invasion and metastasis of breast carcinoma. However, apart from 
these forkheads, two other members of that family have been observed to be 
implicated in breast cancer.  FOXA1 has been found to be overexpressed in 
ERα-positive breast tumours and has been described as a very significant 
transcription factor, driving a plethora of genes to be transcribed. As noted in 
the introduction section, FOXA1 is considered a good prognosis factor in 
breast cancer as it is not present in aggressive and highly metastatic tumours. 
On the other hand, the forkhead transcription factor that has been found to be 
overexpressed in ERα-negative breast tumours which are invasive and 
metastatic is FOXC2. FOXC2 in development is a major factor for proper 
formation of the vasculature of the embryo and is a regulator of angiogenesis. 
 
Taken together this information, it would be interesting to understand how 
these two factors regulate VEGF and subsequently angiogenesis and 
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invasiveness in breast cancer. A potential cross-talk relationship between 
those two transcription factors is studied in this chapter. 
 
5.2 RESULTS OF CHAPTER 5 
 
5.2.1 The transcriptional and translational status of VEGF is affected by 
FOXA1 and FOXC2. 
 
In order to examine the idea that both FOXA1 and FOXC2 regulate VEGF 
expression, these two factors were transiently transfected and thus 
overexpressed in MCF-7 breast cancer cells. The increase of FOXC2 was 
coupled to the increase of VEGF secreted protein and mRNA levels 
(Fig.5.1A), whereas FOXA1 had an opposite effect on the cells. FOXA1 
overexpression was associated to a decrease of VEGF secreted protein and 
mRNA levels (Fig. 5.1B).  
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A) 
 
 
B) 
 
 
 
Figure 5.1 FOXC2 overexpression upregulates VEGF mRNA and protein 
levels in contrast to FOXA1 which downregulates them, in MCF7 cells. 
A) MCF-7 cells were plated out on 6 cm dishes, transfected with the FOXC2-
pCDNA4 expression vector and harvested after 48 h. ELISA was performed in 
order to quantify VEGF in the supernatant of the cells. For VEGF mRNA 
determination, RNA extraction, cDNA synthesis followed by RTqPCR was 
done. L19 was used to normalise the results. B) The exact same procedure 
was followed for MCF-7 cells transfected with the FOXA1-pCDNA3.1 
expression vector. This vector ‘s construction is described in the materials and 
methods section 2.19. 
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It has been shown that FOXA1 and ERα synergize to regulate the 
transcription of target genes in breast cancer, so, to understand if ERα acts as 
a regulator of VEGF via or together with FOXA1, the status of ERα was 
inhibited or activated. 
 
To test this idea, MCF-7-FOXA1 cells which stably overexpress FOXA1 were 
used. Treatment of those cells with either the ERα activator Estradiol (E2) or 
the ERα antagonist ICI182,780 did not alter the effect of FOXA1 
overexpression in MCF-7 cells. FOXA1, independently of ERα, was shown to 
decrease the mRNA expression levels of VEGF (Fig. 5.2). 
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Figure 5.2 FOXA1 represses VEGF mRNA expression independently of 
ERα. MCF-7-FOXA1 overexpressing cells plated out on 6 cm dishes and 
treated with either Ethanol (control), E2 (10-9 nM) or ICI (10-7 nM) for 8 h. The 
cells treated with E2 were growing in an estrogen-free medium, to control the 
sole effect of added E2. The MCF-7 cells were used as a control to the 
FOXA1 overexpressing cells. Cells were harvested, RNA was extracted and 
after cDNA synthesis, RTqPCR was performed. L19 was used as a 
normalising control. 
 
        
 
 
 
 
 
5.2.2 FOXC2 protein expression is repressed by FOXA1 in MCF-7 breast 
cancer cells. 
 
 
As both FOXA1 and FOXC2 regulate VEGF with the exactly opposite results, 
we then assessed the possibility of those two factors to be associated in a 
regulatory relationship between them. It is already known that FOXA1 is a 
 
133 
good prognosis marker in breast cancer, being highly expressed in ERα 
positive tumours. In contrast FOXC2 is considered a poor prognosis factor 
and is associated with metastasis and invasiveness of breast tumour. 
 
Indeed, in MCF-7-FOXA1 overexpressing cells, FOXC2 protein expression 
was significantly repressed. Actually, FOXA1 overexpression, resulted in the 
total absence of FOXC2 protein levels, depending on the sensitivity of the 
western blotting technique (Fig. 5.3A). Although there is a known regulatory 
response of ERα with FOXA1, this response was not a significant in the effect 
of FOXA1 in the repression of FOXC2 (Fig.5.3A). From the data we can 
consider ERα not a player of the FOXA1/FOXC2 interplay. 
 
Moreover, to further test the relationship between FOXA1 and FOXC2, 
FOXA1 was silenced using RNAi. Silencing of FOXA1 in MCF-7 breast cancer 
cells promoted the induction of FOXC2 protein expression (Fig. 5.3B), 
reinforcing our hypothesis. Interestingly, VEGF expression followed a FOXC2 
dependant expressional status, with the absence of FOXA1 favouring its 
increased protein levels. 
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       A) 
 
 
      B)  
                 
 
Figure 5.3 FOXA1 overexpression represses FOXC2 protein expression, 
independently of ERα, whereas its silencing enhances it. A) MCF-7-
FOXA1 and MCF-7 cells were plated out and treated with Ethanol, E2 (10-9 
nM) or ICI (10-7 nM). Cells treated with E2 were growing in a estrogen- 
stripped medium. After harvesting, cells were lysed and proteins were 
separated by SDS-PAGE. Then were immunoblotted with FOXA1 and FOXC2 
antibodies. Tubulin was used to ensure efficient loading. B) MCF-7 cells were 
plated in a 6-well plate, transfected with FOXA1 siRNA using oligofectamine, 
harvested after 48 h and lysed. Proteins were separated by SDS-PAGE and 
immunoblot analysis was done using the FOXA1, FOXC2, VEGF and ERα 
antibodies Immunoblotting against Tubulin was used to ensure efficient 
loading. Non specific (control) siRNA was used to ensure targeted silencing 
efficiency. 
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5.2.3 FOXA1 associates with the promoter of FOXC2, in vitro and in vivo. 
 
To furthermore study the possible interaction of FOXA1 with FOXC2 we 
searched for possible FOXA1 consensus binding sites on its promoter. Indeed 
at the position -683 bp of the FOXC2 promoter the FOXA1 consensus 
TTTGTTTT was found. 
 
To test this interaction, first, we performed oligonucleotide pull-down assay 
experiiments with nuclear lysates from MCF-7 cells treated with either E2 or 
ICI. Western blot analysis of the pulled-down complexes showed that FOXA1, 
which was localized in the nucleus, interacts with FOXA1 binding site of the 
FOXC2 promoter (Fig. 5.4). A competition assay was then performed using 
non-biotiniylated oligos in excess amounts to compete with the biotiniylated 
oligos in the binding of the complex. The binding could be competed off 
suggesting that interaction depends on the FOXA1 site. In all cases of 
treatment FOXA1 was shown to bind on FOXC2, however as expected, the 
levels of FOXA1 in the cells after ICI treatment, were lower than in the cells 
treated with estrogen. 
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Figure 5.4 FOXA1 binds on the promoter of FOXC2. MCF-7 cells were 
treated with Ethanol, E2 (10-9 nM) or ICI (10-7 nM) for 8h, and proteins were 
pulled down using biotin-labelled oligos coupled to streptavidin/sepharose 
beads. The pulled-down complexes were then resolved by SDS-PAGE and 
immunobloted using a FOXA1 antibody. The amount of FOXA1 in the 
cytoplasm was determined by western blotting after cytoplasmic/ nuclear 
fractionation. Tubulin was used as a loading control for both the cytoplasmic 
and whole cell extracts. Cells treated with E2 were growing in an estrogen-
stripped medium. Biotin labeled oligos with excess amounts of site-specific 
oligonucleotides were used to validate the efficiency of the method. 
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Additionally, the interaction of FOXA1 with FOXC2 was tested in the ER- 
negative cell line MDA-MB-231. MDA-MB-231 cells express higher levels of 
both FOXC2 and VEGF, whereas FOXA1 is downregulated.FOXA1 did not 
show any interaction with FOXC2 by oligo-pulldown in the MDA-MB-231 cells 
line (Fig. 5.5A), however this was due to the fact that FOXA1 is repressed in 
these cells.  
 
In order to determine if the FOXA1-FOXC2-VEGF relationship in MDA-MB-
231 cells, FOXA1 was overexpressed by transfection with the FOXA1-
pCDNA3 expression vector. Overexpression of FOXA1 resulted in the 
downregulation of both FOXC2 and VEGF protein expression (Fig 5.5B).  
 
The idea that FOXA1, independently of ERα, is recruited on the FOXC2 
promoter, driving its repression was reinforced. A clear connection between 
the expressional status and an interplay between these two forkhead 
transcription factors resulting in VEGF regulation, could be suggested. 
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A) 
B)  
 
 
 
Figure 5.5 The regulation of VEGF by FOXA1 and FOXC2 in MDA-MB-231 
cells. A) MCF-7 and MDA-MB-231 cells were used for pull down experiments 
using biotin-labelled oligos coupled to strepavidin/sepharose beads. The 
pulled-down complexes were resolved by SDS-PAGE and immunobloted 
using a FOXA1 antibody. 1/10 of the extracts were used as an input and 
visualized by western blotting. Tubulin was used as a loading control. Biotin 
labeled oligos competing with oligos with excess amounts of the FOXA1 site 
were used to validate the efficiency of the method. B) MDA-MB-231 cells 
were transfected using oligofectamine, with the FOXA1-pCDNA3.1 expression 
vector. After 48 h the cells were harvested and lysed. After SDS-PAGE 
separation of the proteins, immunoblotting against FOXA1, FOXC2 and VEGF 
followed. Tubulin was used as a loading control. 
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ChIP was then performed to determine the FOXA1 occupancy on the FOXC2 
promoter, in vivo. FOXA1 was at all different ERα status conditions bound on 
the promoter of FOXC2.  Although as we had seen from previous experiments 
shown above, FOXA1 acts independently of ERα in the regulation of FOXC2 
and subsequently VEGF, still its amounts are affected by ERα. So, FOXA1 
binds on the FOXC2 promoter and regulates its transcription, even in small 
amounts of protein interaction, for example when cells are treated with ICI.  
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Figure 5.6 FOXA1 binds on the FOXC2 promoter, in vivo. MCF-7 cells 
were plated out and treated with Ethanol, E2 (10-9 nM) or ICI (10-7 nM). Cells 
treated with E2 were growing in a estrogen- stripped medium. Protein-DNA 
complexes were cross-linked with formaldehyde. Chromatin fragments were 
undergone immunoprecipitation with a FOXA1 antibody and after de-
crosslinking, the co-immunoprecipitated DNA was amplified by PCR and 
resolved in a 2% agarose gel visualized under UV.  
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5.3 DISCUSSION 
 
 The first steps of trying to understand how the FOXC2 may be regulated in 
breast cancer have already been made in this project. FOXA1, which is 
known to be working in close association with ERα in breast cancer and is 
generally an important transcription factor as it drives the transcription of an 
extremely high number of genes, was shown to highly associate to the 
promoter of FOXC2 driving its repression. This hypothesis was shown at both 
the transcriptional and translation level. This regulation is dependent on the 
association of FOXA1 to its consensus binding site of the FOXC2 promoter. 
Although, FOXA1 is associated to ERα  status, its importance in the 
interaction and repression of FOXC2 was not that significant. FOXA1 
overexpression was not affected by ERα  degradation by ICI and even on the 
promoter area of FOXC2, FOXA1 was shown to interact, in lower levels 
however.  
 
The event which was clearly observed is that the presence of FOXA1 in the 
nucleus of breast cancer cells dictates and is associated with a lower 
expression of FOXC2, and in reverse, the absence of FOXA1 by siRNA leads 
to the upregulation of FOXC2. This expressional pattern affects the 
expression of VEGF in the same exact way, proposing a mechanism of VEGF 
regulation which potentially could be assessed to target angiogenesis and 
invasiveness in breast cancer.  
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